

Review

Not peer-reviewed version

DUBing Primary Tumors of the Central Nervous System: Regulatory Roles of Deubiquitinases

[Thomas Klonisch](#) , [Susan E. Logue](#) , [Sabine Hombach-Klonisch](#) , [Jerry Vriend](#) *

Posted Date: 12 September 2023

doi: 10.20944/preprints202309.0749.v1

Keywords: brain tumor; glioma; neuronal system tumor; deubiquitinase (DUB); Endoplasmic Reticulum Associated Degradation (ERAD); immune response; therapeutic target; DNA repair



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

DUBing Primary Tumors of the Central Nervous System: Regulatory Roles of Deubiquitinases

Thomas Klonisch ^{1,2,3,4}, Susan E. Logue ^{1,4}, Sabine Hombach-Klonisch ^{1,2} and Jerry Vriend ^{1,*}

¹ Depts. of Human Anatomy and Cell Science, CancerCare Manitoba, Rady Faculty of Health Sciences, College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

² Depts. of Pathology, CancerCare Manitoba, Rady Faculty of Health Sciences, College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

³ Depts. of Medical Microbiology & Infectious Diseases, CancerCare Manitoba, Rady Faculty of Health Sciences, College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

⁴ Depts. of CancerCare Research Institute, CancerCare Manitoba, Rady Faculty of Health Sciences, College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

* Correspondence: Dr. J. Vriend, Department of Human Anatomy & Cell Science, Rm134, BMSB, 745 Bannatyne Avenue, Max Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, R3E 0J9, Canada; email: Jerry.Vriend@umanitoba.ca

Abstract: The ubiquitin proteasome system (UPS) utilizes an orchestrated enzymatic cascade of E1, E2, and E3 ligases to add single or multiple ubiquitin-like molecules as post-translational modification (PTM) to proteins. Ubiquitination can alter protein functions and/or marks ubiquitinated proteins for proteasomal degradation but deubiquitinases (DUBs) can reverse protein ubiquitination. While the importance of DUBs as regulatory factors in the UPS is undisputed, many questions remain on DUB selectivity for protein targeting, their mechanism of action, and the impact of DUBs on the regulation of diverse biological processes. Furthermore, little is known about the expression and role of DUBs in tumors of the human central nervous system (CNS). In this comprehensive review, we have used publicly available transcriptional datasets to determine the gene expression profiles of 99 deubiquitinases (DUBs) from five major DUB families in seven primary pediatric and adult CNS tumor entities. Our analysis identified selected DUBs as potential new functional players and biomarkers with prognostic value in specific subtypes of primary CNS tumors. Collectively, our analysis highlights an emerging role for DUBs in regulating CNS tumor cell biology and offers a rationale for future therapeutic targeting of DUBs in CNS tumors.

Keywords: brain tumor; glioma; neuronal system tumor; deubiquitinase (DUB); Endoplasmic Reticulum Associated Degradation (ERAD); immune response; therapeutic target; DNA repair

Introduction

The ubiquitin proteasome system (UPS) is a highly regulated and dynamic process that utilizes a three-step enzymatic cascade to attach small molecules of the ubiquitin family onto proteins to alter their function and/or mark ubiquitinated proteins for proteasomal degradation. The extensive Ubiquitin and Ubiquitin-like Conjugation Database (UUCD) lists enzymes involved in ubiquitin post-translational modification of proteins¹. In eukaryotes, this includes one human ubiquitin-activating (E1) enzyme, 43 E2 ubiquitin-conjugating enzymes, 468 enzymes with E3 ligase activity, 538 E3 ligase adaptors, and approx. 100 de-ubiquitin enzymes (DUBs)^{2,3}. Ubiquitin is one of several ubiquitin-like protein modifiers that also includes ubiquilins, SUMO, NEDD8, and ISG15⁴. While cellular regulators in their own right, these post-translational modifiers can cross-communicate with ubiquitin through modifications or are being modified by (poly)ubiquitin⁵. Ubiquitin has eight ubiquitination sites, including seven lysine (K) residues (K6, K11, K27, K29, K33, K48, K63) and a primary amine at the N-terminus⁵. While mono-ubiquitination and K48- and K63-linked polyubiquitination are the most abundant forms, multiple other types of ubiquitination exist which have distinct functional outcomes⁶. Monoubiquitination refers to the attachment of a single ubiquitin molecule to a target protein and serves as a signal for protein recognition, complex formation, or allosteric regulation. The addition of a single ubiquitin moiety during mono-ubiquitination can

influence the localization, activity, or interaction of the modified protein within the cell. Polyubiquitination refers to the formation of a covalently linked ubiquitin molecule chain attached to a specific lysine residue of ubiquitin. When a protein is polyubiquitinated with K48-linked ubiquitin chains, it is recognized by the proteasome and targeted for degradation. Unlike K48-linked ubiquitin chains, K63-linked ubiquitin chains do not target proteins for degradation but enable context specific functions of K63 ubiquitinated proteins in cellular signaling, intracellular trafficking, autophagy, and DNA damage responses^{7,8}. K63-linked ubiquitin chains serve as scaffolds for protein-protein interactions, modulate enzyme activity, and regulate the localization and function of target proteins^{9,10}.

Deubiquitinating enzymes (DUBs) contribute to the regulation of a variety of biological processes, including proteasomal degradation of proteins, cell cycle regulation, histone modifications, transcriptional and translational control, protein trafficking, macro- and mitophagy, DNA damage response, epigenetic processes, and immune response signaling⁵. DUBs reverse the process of protein ubiquitination by selectively removing ubiquitin molecules or chains from proteins. Hence, DUBs are editors of the ubiquitin code and remove single ubiquitin molecules, entire ubiquitin chains, or ubiquitin branches from a ubiquitinated protein by cleaving ubiquitin substrate bonds and ubiquitin-ubiquitin peptide bonds^{11,12}. The approx. 100 putative DUBs identified so far in the human proteome are classified into five major families based on their structural and functional characteristics¹³⁻¹⁵. The ubiquitin-specific proteases (USP) are the largest subclass of DUBs, with currently 54 members in humans¹⁶. USPs contain a conserved catalytic domain known as the ubiquitin-specific protease domain and exhibit specificity towards different types of ubiquitin linkages. Ubiquitin carboxy-terminal hydrolases (UCH) family members (4 members) possess a distinct catalytic domain called the UCH domain. UCHL members are involved in the processing of ubiquitin precursors and the removal of ubiquitin from proteins¹⁷⁻¹⁹. DUBs of the ovarian tumor proteases (OTU) family (16 members) contain an ovarian tumor (OTU) domain and are involved in various cellular processes, including immune signaling, pathogen infection, and DNA damage response²⁰⁻²². The Machado-Joseph disease proteases (MJD) family of DUB proteins (4 members) possess a Josephin domain, prefer K48/ K63 linkages, and are associated with neurodegenerative disorders, particularly Machado-Joseph disease²³. The JAB1/ MPN/ Mov34 (JAMM) metalloenzyme family (16 members) of DUBs contains a metalloprotease domain and prefers targeting K63 ubiquitination sites. JAMM member CSN5 is a deNEDDylase²⁴⁻²⁶. The MINDY family is a recent DUB addition, with two of the 4 family members containing a "motif interacting with ubiquitin" (MIU) which assists in the enzymatic cleave of long K48 polyubiquitin chains²⁷. Finally, a diverse group of ubiquitin-like proteases (ULPs) targets ubiquitin-like modifiers other than ubiquitin and comprises SENP (sentrin/ SUMO-specific protease), DeSI (deSUMOylating isopeptidase) families], and NEDD8²⁸⁻³⁰.

DUBs are essential for the dynamic and coordinated actions of the UPS and ensure proper functions of virtually all cellular processes, including the control of cellular levels of key regulatory transcription factors, growth factors, morphogens, cell cycle regulators, and the balance of factors regulating cell survival. The enzymatic removal of ubiquitin groups by DUBs is critical for reversible ubiquitination and the recycling of unbound ubiquitin to the UPS and ERAD (endoplasmic reticulum-(ER) associated degradation) pathways. Cellular DUB activity determines the coordinated regulation of both the UPS and ERAD pathways in a tissue region- and context-specific manner³¹.

Extending throughout eukaryotic cells, the ER is the largest cellular organelle and composed of a series of sheet like and tubular structures that form close contacts with other organelles, in particular the nucleus and mitochondria³². The ER can be subdivided into two types, the smooth and the rough ER. While the smooth ER facilitates lipid synthesis and hormone synthesis, the rough ER is the site of protein folding, modification, and quality control³². Signal peptides direct newly synthesized proteins to the ER lumen where ER localized chaperones and enzymes facilitate protein folding and modifications. Correctly folded and processed proteins are then shuttled, via transport vesicles, to the Golgi apparatus and from there to their final destination³³. The folding and modification of proteins is highly dependent on the maintenance of a stable ER environment. Exposure to stresses,

such as oxygen and glucose deprivation or loss of ER calcium lowers protein folding efficiency resulting in the accumulation of unfolded/ misfolded proteins³⁴. ER function can also be compromised by protein folding demands exceeding capacity. An example being viral infections where the capacity of the ER to facilitate protein folding is overwhelmed, giving rise to misfolded proteins³⁵. Irrespective of the initiating stimulus, the buildup of misfolded/ unfolded proteins is commonly referred to as ER stress. Cells combat ER stress by initiating an adaptive, highly conserved stress response referred to as the Unfolded Protein Response or UPR. The UPR is controlled by three ER anchored transmembrane receptors, Inositol-requiring enzyme 1 (IRE1), protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) and activating transcription factor 6 (ATF6). These three ER-based receptors monitor ER health. In an unstressed setting, each of these stress sensors is held in an “off” position by binding of their luminal domain to the ER chaperone Grp78 (BIP, HSPA5)^{36, 37}. Upon ER stress, Grp78 dissociates from IRE1, PERK, and ATF6 which stimulates their transition from inactive to active states^{36, 37}. Downstream signaling pathways orchestrated by IRE1, PERK, and ATF6 function in a co-operative, complementary manner to support the refolding of those proteins that can be refolded. Those proteins beyond repair are removed via the ER associated degradation or ERAD pathway³⁴. Ultimately, the objective of the UPR is to reduce ER stress, thereby restoring ER homeostasis.

Cancer cells frequently endure both external stressors (e.g., hypoxia and glucose deprivation) and internal stresses triggered by their high proliferation and metabolic rate. To thrive under such conditions and escape immune responses, cancer cells engage and coordinate adaptive responses, including UPS, ERAD, UPR, DNA damage repair³⁸⁻⁴¹. Although these responses may initially be engaged to aid cellular stress adaptation, cancer cells usurp and/ or co-opt these pathways for their benefit in numerous ways. We recently identified distinct gene expression changes in ubiquitin ligases and ligase adaptors in different human brain tumors and subtypes^{42, 43}. Sustained UPR signaling has been reported in diverse cancers including breast, prostate, and brain cancers and emerging evidence links ERAD and UPR to an array of pro-tumorigenic processes, including angiogenesis, metastasis, and cancer stem cell expansion³⁸.

DUBs are an integral part of the UPS but their role in human brain tumors is incompletely understood. Understanding the role of DUBs in brain tumors could yield new therapeutic avenues. In the present study, we have analyzed the gene expression profiles of 99 human DUBs belonging to 7 subgroups listed in the HUGO (Human genome organization) classification. The objective of the current study was to examine the differential gene expression of these DUBs in publicly available datasets of selected human neuronal system tumors, including pediatric (craniopharyngioma (CPh), ependymoma (EPN), medulloblastoma (MB), adult brain tumors (astrocytoma (AS), oligodendroglioma (ODG), glioblastoma (GBM), and neuroblastoma (NBT) as the most common childhood extra-cranial solid tumor arising from the developing sympathetic nervous system^{44, 45}. Some of the datasets had available gene expression data of non-tumor tissues for comparison while other datasets had available age data for each subject. This allowed for plotting gene expression by tumor subgroup and by age for each DUB and enabled the comparison of gene expression in pediatric vs adult age groups. We sought to determine whether expression of DUB genes was selective for specific tumors, specific subgroups of tumors, or specific age groups of subjects with these brain tumors. For those datasets with survival data, we determined whether DUB gene expression was statistically associated with survival. Top DUB hits identified in these bioinformatic screens were interrogated for their association with ERAD, UPR, and DNA repair. This is the first comprehensive report with a focus on DUB family members in selected pediatric and adult brain tumors, their relationship with ERAD, UPR, DNA damage repair pathways, and their suitability as potential biomarkers and therapeutic targets.

Methods

We utilized the human genome list of 99 deubiquitinases to determine the expression of these DUB genes in publicly available datasets of brain tumors. Differential expression of DUB genes was examined in these datasets made available in the R2 Genomics Analysis and Visualization platform

(<https://r2.amc.nl>). We used the AS, GBM, ODG, and a non-tumor group in the mixed glioma dataset of Sun et al (Geo ID: GSE4290). Differentially expressed DUB genes were considered significant at $p < 0.001$ as determined by Analysis of Variance (ANOVA) through the R2 Genomics site and plotted using the Morpheus heatmap and cluster analysis program at the Broad Institute website (<https://software.broadinstitute.org/morpheus>). DUB gene expression of classic, mesenchymal, and proneural GBM subtypes were examined in the TCGA GBM dataset (R2 ID: Tumor Glioblastoma TCGA 540). Survival data associated with differentially expressed DUB genes was examined in the French glioma data (GSE16022)⁴⁶. The Pfister dataset (GSE64415) was used to examine differentially expressed DUB genes in ependymoma. A dataset of Donson (GSE94349) was used to examine differential expression of DUB genes in CPh, while the datasets of Cavalli et al.⁴⁷ (GSE85217) and Weishaupt et al.⁴⁸ (GSE124814) were used to examine DUB gene expression in MB subgroups. The Cavalli dataset had extensive data on the age of subjects in the various subgroups, which we used to determine the age distribution for the most highly significant differentially expressed DUB genes. Those DUB genes statistically associated with survival of MB patients were also determined in the Cavalli dataset. The Weishaupt data (Swartling dataset in the R2 Genomics database) allowed for a comparison of genes between MB tumor tissue and non-tumor tissue. The NBT dataset of Fischer⁴⁹ (GSE120572) was used to evaluate various treatment effects on DUB expression. The Cytoscape program was applied to identify gene ontology (GO) pathways, including ERAD, DNA repair, immune response pathways, and genes coding for differentially expressed DUBs that were associated with brain tumors.

Results

Cytoscape analysis of the 99 DUB genes (GO biological pathways) identified several functional groups of DUBs involved in the deubiquitination of lysine (K) residues K6/ K11/ K27/ K29/ K48/ K63 ubiquitinated proteins. The most significant biological pathways, other than deubiquitination itself, included DNA repair, DNA methylation, the regulation of ER stress and ERAD pathway, death receptor signaling, and the regulation of immune and cytokine responses.

Adult Glioma Show Differential Expression of DUBs

In the Sun mixed glioma dataset, expression of 51 of the 99 DUB genes (HUGO classification) were significantly different ($p < 0.001$) between the four groups in the dataset (non-tumor, AS, GBM, ODG). The heatmap (**Fig. 1**) shows the gene expression profiles of the four groups. **Table 1** shows the DUB genes that were most significantly different between the non-tumor group and each of the other three adult glioma groups. Seventeen of the 99 DUB genes were differentially expressed ($p < 0.001$) between AS, ODG, and GBM (*USP46*, *USP54*, *ZRANB1*, *USP1*, *OTUD7A*, *TNFAIP3*, *USP27x*, *USP30*, *EIF3H*, *USP49*, *OTUD1*, *USP11*, *OTUB1*, *CYLD*, *USP12*, *USP2*, *USP47*; in order of p value as determined by ANOVA).




Figure 1. Heatmap and cluster analysis of differentially expressed DUBs in gliomas. Non-tumor, N = 23; Astrocytoma, N = 26; Glioblastoma, N = 77; Oligodendroglioma, N = 50).


Table 1. Top ten differentially expressed DUB genes in gliomas by group compared to non-tumor group.

Astrocytoma ¹	DUB	<i>p</i> value (corrected)	Chromosome	Versus non-tumor group in the Sun dataset
<i>CYLD</i>	Usp	2.44E-13	16	Down
<i>USP12</i>	Usp	3.73E-12	13	Down
<i>USP3</i>	Usp	1.95E-11	15	Up
<i>OTUD7A</i>	Otu	1.26E-10	15	Down
<i>OTUB1</i>	Otu	4.38E-10	11	Down
<i>USP8</i>	Usp	1.69E-09	15	Up
<i>USP33</i>	Usp	8.97E-09	1	Down
<i>STAMBPL1</i>	Jamm	5.64E-08	10	Down
<i>EIF3F</i>	Jamm	5.94E-08	11	Up
<i>EIF3H</i>	Jamm	4.60E-07	8	Up
Glioblastoma²				
<i>USP12</i>	Usp	5.22E-20	13	Down
<i>OTUD7A</i>	Otu	1.13E-19	15	Down
<i>ZRANB1</i>	Otu	2.37E-18	10	Down
<i>USP46</i>	Usp	3.60E-18	4	Down
<i>OTUB1</i>	Otu	4.24E-18	11	Down
<i>CYLD</i>	Usp	2.34E-16	16	Down
<i>USP3</i>	Usp	1.20E-13	15	Up
<i>USP27X</i>	Usp	5.35E-12	X	Down
<i>USP30</i>	Usp	9.20E-12	12	Down
<i>USP11</i>	Usp	1.39E-11	X	Down

Oligodendroglioma³				
<i>USP12</i>	Usp	3.27E-11	13	Down
<i>OTUD7A</i>	Otu	3.55E-10	15	Down
<i>USP48</i>	Usp	6.67E-09	1	Down
<i>USP33</i>	Usp	1.37E-08	1	Down
<i>CYLD</i>	Usp	1.45E-08	16	Down
<i>USP3</i>	Usp	1.50E-08	15	Up
<i>EIF3F</i>	Jamm	1.57E-08	11	Up
<i>OTUD3</i>	Otu	2.46E-08	1	Down
<i>USP14</i>	Usp	4.85E-08	18	Down
<i>OTUB1</i>	Otu	6.68E-08	11	Down

¹ total of 24 DUBs different from NT at $p < 0.0001$; ² total of 43 DUBs different from NT at $p < 0.0001$; ³ total of 30 DUBs different from NT at $p < 0.0001$.

Next, we asked whether the differences in DUB gene expression between AS and GBM were related to the progression from AS to GBM which is associated with several changes in the transcriptome⁵⁰. ANOVA showed that the expression of two DUB genes, *USP46* and *ZRANB1*, differed at a high level of significance ($p < 0.001$) between the AS and GBM group (Fig. 2). *USP46* was among the top 100 of all differentially expressed genes between the AS and GBM groups in the Sun mixed glioma dataset. Of all 18,896 genes in the French dataset, *ZRANB1* and *USP46* expression were ranked 3rd and 2725th respectively when associated with survival. *ZRANB1* belongs to the OTU class of DUBs and has been reported as an EZH2 (Enhance of zeste homolog 2) DUB⁵¹. EZH2 inhibitors are currently tested for cancer therapy and brain permeable derivatives may offer new avenues in the treatment of brain tumors^{52, 53}.






Figure 2. Differential expression of *USP46* and *ZNRANB1* in adult glioma groups. *USP46* ($F = 42.34$, $p = 1.53e-20$); *ZNRANB1* ($F = 45.17$, $p = 1.40e-21$) in the Sun dataset; Non tumor $N = 23$, Astrocytoma, $N = 26$, Glioblastoma, $N = 77$, Oligodendroglioma, $N = 50$).

Chromosome 10 and DUB Expression in Astrocytic Glioma

The loss of chromosome 10 in primary GBM or loss of the q arm of chromosome 10 in secondary GBM is a common finding^{54, 55}. This has led to the hypothesis that the loss of one or more tumor suppressor genes on the q arm of chromosome 10 may contribute to GBM development. The most significant differentially expressed pathway between the AS and GBM group in the Sun dataset was the “*D-glutamine and D-glutamate*” pathway which was represented by differential expression of two genes, *GLUD1* and *GLUD2* (glutamate dehydrogenase 1 and 2). *GLUD1* is located on chromosome 10 and codes for the mitochondrial matrix enzyme glutamate dehydrogenase 1. Several differentially expressed DUB genes, including *ZNRANB1*, are also located on chromosome 10. The HUGO list of DUB genes includes two DUBs located on the p arm of chromosome 10 (*OTUD1* and *MINDY3/FAM188A*) and three DUBs that are located on the q arm of chromosome 10 (*ZNRANB1*, *USP54*, and *STAMBPL1*). Expression of *ZNRANB1* and *USP54* was depressed in the GBM group compared to the AS and non-tumor groups. Similarly, *GLUD1* expression was lowered to 52.7% and 52.2% compared to the NT and AS groups, respectively. While a role for specific DUBs in the regulation of *GLUD1* has not been established, among all 99 DUB genes we observed highest correlations of *GLUD1* expression with *USP46* ($r = 0.74$, $p = 1.74e-30$) and *ZNRANB1* ($r = 0.70$, $p = 1.01e-26$). This may suggest a possible new role for *USP46* and/ or *ZNRANB1* in the regulation of *GLUD1* in astrocytic glioma (AS and GBM).

Differential Expression of DUBs in GBM Subtypes

The differential expression of DUB genes was determined in three GBM subtypes from a TCGA dataset in the R2 genomics platform. *TNFAIP3* showed the most significant difference ($p = 7.68e-09$) in expression with elevated expression in the mesenchymal GBM subtype (Fig. 3). The DUBs with the most significantly elevated gene expression in the proneural GBM group were *USP11*, *USP22*, and *USP7*.




Figure 3. Heatmap and cluster analysis of DUB genes differentially expressed in GBM subtypes. On average, TNFAIP3 expression was higher in the GBM mesenchymal group, whereas the expression of the other 9 genes was greater in the proneural group. Classic, N = 17; Mesenchymal, N = 27; Proneural, N = 24).

Relationship Between DUB Expression and Survival (French Dataset)

Survival data were not available in the Sun mixed glioma dataset. Hence, we used the glioma dataset (GSE16011) of French et al.⁴⁶ (N = 284) to determine survival data associated with DUB gene expression. Kaplan Meier curves showed that the expression of 23 DUB genes was significantly associated ($p < 0.001$) with survival in glioma patients. **Table 2** lists the Chi square, p values, and hazard ratios for these DUB genes. The most significantly downregulated DUB, *ZRANB1* (as would be expected with loss of chromosome 10 or its q arm), was associated with worse survival. p

Table 2. DUB gene expression and survival data of glioma patients (French dataset).

DUB Gene	Family	Chromo- some	Chi square Kaplan Meier	p value	Hazard Ratio (HR)	HR p value	Better survival
<i>ZRANB1</i>	Otu	10	116.69	3.36e-27	0.21	4.6e-27	High
<i>FAM188A</i>	Mindy	10	68.95	1.01e-16	0.53	1.4e-13	High
<i>USP34</i>	Usp	2	63.01	2.06e-15	0.30	4.4e-12	High
<i>USP49</i>	Usp	6	63.46	1.63e-15	0.55	1.9e-16	High
<i>Usp27X</i>	Usp	X	57.58	3.24e-14	0.43	1.6e-15	High
<i>USP54</i>	Usp	10	51.46	7.30e-13	0.68	2.5e-11	High
<i>USP51</i>	Usp	X	49.10	2.43e-12	0.69	1.4e-11	High
<i>USP30</i>	Usp	12	43.77	3.69e-11	0.47	1.5e-8	High
<i>USP11</i>	Usp	X	42.18	8.33e-11	0.52	2.6e-10	High
<i>OTUD7A</i>	Otu	15	38.15	6.54e-10	0.69	1.3e-9	High
<i>EIF3H</i>	Jamm	8	35.16	3.40e-09	0.47	7.1e-10	High
<i>USP1</i>	Usp	1	33.71	6.39e-09	1.8	1.4e-8	Low
<i>USP4</i>	Usp	3	33.07	8.90e-09	2.6	5.6e-8	Low
<i>ATXN3</i>	MJD	14	33.10	8.75e-09	0.65	7.7e-6	High
<i>USP43</i>	Usp	17	31.76	1.74e-08	0.74	1.1e-8	High
<i>USP46</i>	Usp	4	31.45	2.05e-08	0.65	9.2e-8	High
<i>TNFAIP3</i>	Otu	6	30.86	2.77e-08	1.3	6.0e-7	Low
<i>OTUD1</i>	Otu	10	28.27	1.06e-07	0.54	2.0e-8	High

<i>JOSD2</i>	MJD	19	25.88	3.62e-07	1.5	2.1e-4	Low
<i>PSMD7</i>	Jamm	16	24.22	8.60e-07	1.9	1.3e-4	Low
<i>STAMBPL1</i>	Jamm	10	23.87	1.03e-06	0.76	4.3e-5	High
<i>USP14</i>	Usp	18	23.95	9.90e-07	2.1	1.0e-4	low

Role of DUBs in ER Stress and ERAD Signaling in Glioma

Employing the R2 genomics platform to query the 99 DUBs for their association with the GO category of *regulation of ERAD pathway*, we identified three DUB genes in this category as differentially expressed in the glioma dataset: *USP14*, *USP19*, and *USP25* (**Table 3**); it should be noted, however, that only *USP14* was among the most significant in **Table 1**. In the French dataset high *USP14* expression was associated with worse survival (**Table 2**). The role of *USP14* and *USP19* proteins in ER stress has been illustrated in a review by Qu et al.³¹. *USP19* is reported to inhibit the unfolded protein response⁵⁶ and to deubiquitinate the E3 ligase HRD1⁵⁷, a component of the ERAD pathway. *USP14* binds to IRE1 and is reported to be an inhibitor of the ERAD pathway⁵⁸. *USP25* deubiquitinates selected ERAD substrates⁵⁹. Another DUB reported by Qu et al. to regulate ER stress induced apoptosis is *BAP1*³¹. Differential *BAP1* gene expression is also shown in **Table 3**.

Table 3. Differential expression of DUBs in ERAD signaling in glioma.

DUB gene	Non-tumor N = 23	Astrocytoma N = 26	Glioblastoma N = 77	Oligodendroglioma N = 50
<i>USP14</i>	851.87 ± 25.31	689.66 ± 25.63*	738.5 ± 18.13*	647.71 ± 16.28*
<i>USP19</i>	159.11 ± 6.47	206.93 ± 9.5*	222.11 ± 6.09*	226.03 ± 7.9*
<i>USP25</i>	314.57 ± 14.19	216.77 ± 9.34*	216.88 ± 9.18*	209.77 ± 7.59*
<i>BAP1</i>	295.14 ± 10.78	221.5 ± 7.97*	244.66 ± 5.02*	248.25 ± 6.88*

USP14 (F = 12.27, p = 2.58e-07), *USP19* (F = 10.53, p = 2.16e-06), *USP25* (F = 14.59, p = 1.64e-08), *BAP1* (F = 11.06, p = 1.12e-06); * Significantly different from non-tumor group at p < 0.001.

DUBs in the Regulation of Immune Responses in Glioma

Among the 99 DUB genes, four differentially expressed genes were identified in the Sun glioma dataset that associated with the GO category of *Regulation of the immune response*. This included *OTUD7A*, F = 69.909, p = 1.31e-29, *CYLD*, F = 50.614, p = 1.69e-23, *TNFAIP3*, F = 11.84, p = 4.34e-07, and *USP18*, F = 8.14, p = 4.21e-05 (**Fig. 4**). Notably, expression of *OTUD7A* was not only most significantly different of the DUBs in the GO category of *Regulation of immune response* but was also the most significant of any of the 512 genes in this category in the Sun dataset. *OTUD7A* expression was significantly depressed in AS, GBM, and ODG (**Fig. 4**), as was *OTUB1* in all three types of gliomas compared to non-tumor tissues in the Sun dataset (**Table 1**). *OTUB1* deubiquitinase function was recently associated with the regulation of immune responses and contributes to immunosuppression in cancers via the programmed death ligand 1 (PD-L1) protein⁶⁰. Decreased *OTUB7A* and *OTUB1* gene expression may both affect immune responses and DNA damage repair functions (see below) in glioma^{60, 61}.




Figure 4. Differentially expressed DUBs identified under the GO category of *Regulation of immune response* in different glioma and non-tumor brain. * $p < 0.001$ compared to non-tumor group.

The *OTUD7a* gene is located on chromosome 15q13.3. Microdeletion of this chromosomal region results in abnormalities of neuronal development^{62, 63}. *CYLD* is a tumor suppressor that contributes to regulation of NF- κ B⁶⁴. *TNFAIP3* plays a role in several aspects of the immune response, including regulation of NF- κ B and regulation of inflammation⁶⁵. *TNFAIP3* deletions have been associated with Epstein-Barr viral infection in lymphomas⁶⁶. *USP18* regulates interferon signaling by binding to one of its receptors (IFNAR2)⁶⁷.

DUBs and DNA Repair in Glioma

Ten of the 99 DUB genes analyzed in the Sun dataset were differentially expressed genes associated with the GO category of *DNA repair*: *OTUB1*, *UCHL5*, *USP3*, *USP1*, *USP51*, *COPS5*, *COPS6*, *USP10*, *USP47*, *USP43* (in order of significance in ANOVA). The expression of *OTUB1* and *UCHL5* was significantly decreased ($p < 0.001$) in AS, GBM, and ODG compared to non-tumor tissue, while the expression of *USP3* was significantly elevated ($p < 0.001$) (Fig. 5). Expression of *USP1* was markedly increased in GBM and, to a lesser extent, in AS compared to the non-tumor group. Several DUBs, including *USP1*, *OTUB1*, *UCHL5*, and *USP47*, have been included in a list of 16 DUBs reported to be involved in specific DNA damage repair pathways⁶⁸. *OTUD7A* (Cezanne2) has also recently been reported to contribute to the DNA damage response to double strand break (DSB) repair⁶⁹ and expression of *OTUD7A* was substantially reduced in gliomas compared to non-tumor brain tissue (Fig. 4). While linked to several DNA repair pathways⁶⁸, *USP7* and *USP24* expression was not significantly different among glioma groups or between glioma and the non-tumor control group in the Sun dataset, suggesting that these two DUBs may not be critical factors in DNA damage repair pathways in glioma.




Figure 5. Differentially expressed DUB genes in the GO category of DNA repair. *UCHL5*, $F = 21.83$, $p = 4.97\text{e-}120$; *OTUB1*, $F = 42.71$, $p = 1.12\text{E-}20$; *USP3*, $F = 19.33$, $p = 7.56\text{e-}11$; *USP1*, $F = 16.99$, $p = 1.04\text{e-}09$. * $p < 0.001$ compared to Non tumor group by t-test.

DUBs in Ependymoma

The heatmap and cluster analysis shown in **Figure 6** illustrates clusters of DUB gene expression that differ significantly between the EPN subgroups of the Pfister dataset. Of all molecular subgroups in this dataset, the largest groups were the posterior fossa groups, Pf_Epn_a (N = 72) and Pf_Epn_b (N = 39) followed by the supratentorial group (St_Epn_Rel) (N=49). Among all 99 DUBs, *USP30* and *STAMBPL1* were most significantly different in these 3 EPN subgroups. *USP30* expression most significantly distinguished Pf_Epn_a and Pf_Epn_b, whereas *STAMBPL1* expression was depressed compared to the other subgroups (**Fig. 7**).




Figure 6. Heatmap and cluster analysis of DUB gene expression in ependymoma subtypes (Pf_Epn_a, N = 72; Pf_Epn-b, N = 39; Pf_se, N = 11; Sp_Epn, N = 11; Sp_Mpe, N = 8; St_Epn_Rela, N = 49; St_Epn_Yap1, N = 11; St_Se, N = 8).

The UPS30 protein is located on the mitochondrial outer membrane⁷⁰ and serves as an inhibitor of mitophagy^{71, 72} by blocking the action of the E3 ligase PARKIN⁷³. STAMBPL1 is a K63 specific DUB reported to be expressed higher in cancer tissue than in adjacent control tissues^{74, 75}.




Figure 7. Differential expression of *USP30* and *STAMBPL1* in ependymoma molecular subgroups. *USP30*, $F = 12.58$, $p = 2.38 \times 10^{-13}$; *STAMBPL1*, $F = 54.29$, $p = 5.23 \times 10^{-43}$. This dataset is missing non-tumor control group for comparison by t test.

The heatmap of DUB expression in EPN subgroups (Fig. 6) showed a cluster with relatively elevated DUB expression in the St_Rela subgroup (red squares in heatmap) and a cluster in which DUB expression was relatively depressed (blue squares in heatmap). Cytoscape analysis of GO

biological pathways identified several DUBs associated with *histone deubiquitination* in both clusters. This included the upregulated expression of *BAP1*, *USP25*, *USP3*, *USP49* (red squares) and downregulated expression of *USP16*, *USP21*, *USP22*, and *USP51* (blue squares) (Fig. 6). Cytoscape Reactome pathway analysis of differentially expressed DUB genes in Fig. 6 identified the expression of three DUB genes, *CYLD*, *USP2*, and *USP21*, to be associated with the TRAF2:RIP1 complex in Tumor necrosis factor receptor (TNFR) signaling and apoptosis. The UPS2 protein has been labeled a “master regulator of apoptosis” since USP2 can remove ubiquitin chains from RIP1 and TRAF2, regulate TNF-TNFR1 mediated cell death, and upregulate the transcription of I κ B α ⁷⁶. Like USP2, USP21 was also reported to deubiquitinate RIP1⁷⁷ and a selective USP21 inhibitor, compound BAY-805, may have therapeutic potential in cancer⁷⁸. Both, *CYLD* and *TNFAIP3* have been shown to also contribute to the regulation of NF- κ B^{64, 66}. Notably, the supratentorial molecular subgroup St_Se of EPN was unique in that it showed increased expression of a cluster of four DUB genes, *CYLD*, *USP46*, *USP53*, *USP32* (Fig. 6). This may be considered a new gene signature for this WHO grade I subependymoma (Se) subgroup⁷⁹. Among the significant differentially expressed DUBs in the EPN dataset were five genes associated with the *Regulation of ERAD pathway*, including *ATXN3*, *USP3*, *USP14*, *USP25*, and *OTUD2/YOD1*. Since the Pfister ependymoma dataset did not include non-tumor subjects or survival data, these comparisons were not possible for the DUB genes.

DUBs in Craniopharyngioma

Of the 99 DUB genes analyzed, 39 DUBs were differentially expressed between normal brain and CPh. Other than DUB activity itself, *histone deubiquitination* (USP3, USP7, USP16) was the most significant GO pathway identified by Cytoscape.




Figure 8. Heatmap and cluster analysis of DUB genes in craniopharyngioma. Normal, N = 27; Craniopharyngioma, N = 24.

USP13 (F = 24.25, p = 1.00 e-05) and USP14 (F = 11.88, p = 1.17e-03) expression were both depressed in CPh compared to non-tumor tissue (Fig. 8). Of note, differential expression of USP14 was also observed in mixed gliomas and in EPN. USP14 protein was reported to be an inhibitor of

the ERAD pathway by binding to IRE1a and inhibiting the phosphorylation of this ER stress activated kinase⁸⁰.

DUB Regulation of Immune Response in Craniopharyngioma

In the dataset of CPh, the DUB genes *TNFAIP3*, *OTUD7A*, and *CYLD* were identified by Cytoscape to be associated with the *Regulation of immune response* pathway. *TNFAIP3* expression was upregulated about 5-fold ($F = 78.84$, $p = 9.93\text{e-}12$) compared to non-tumor tissue. *TNFAIP3* has been identified as a druggable targeted for melanoma in mice⁸¹ and in inflammatory lung disease⁸². Expression of *OTUD7A* (aka Cezanne2) in CPh was significantly downregulated to 6.8% of normal non-tumor values ($F = 81.52$, $p = 5.34\text{e-}12$). Located on chromosome 15, *OTUD7A* is one of six genes that contribute to the 15q13.3 microdeletion syndrome, which is associated with neurodevelopmental and psychiatric disorders^{83, 84}. Whether *OTUD7A* protein may qualify as tumor suppressor for the development of CPh tumors (and gliomas, see above), as these data may suggest, requires further studies. Expression of the DUB and tumor suppressor *CYLD* was significantly reduced (>50%) in CPh compared to normal brain tissue. *CYLD* is an inhibitor of the immune response and NF- κ B signaling⁸⁵⁻⁸⁷.

DUBs and Medulloblastoma

Of the 99 DUB genes, 78 were differentially expressed ($p < 0.001$) among the four subgroups of MB. **Table 4** shows the top ten DUB genes of each MB subgroup most significantly different from non-tumor tissues in the Swartling dataset. The heatmap in **Fig. 9** illustrates the distribution of DUB expression among the four MB subgroups (Group 3, Group 4, SHH, and WNT) in the Cavalli dataset. The most significant differentially expressed DUB gene by subgroups in the Cavalli dataset was *USP2* ($F = 271.00$, $p = 1.57\text{e-}119$) (**Fig. 9**), which was upregulated in Group 3 MB compared to the other subgroups. *USP2* protein removes ubiquitin from several proteins, including the E3 ubiquitin ligase MDM2⁸⁸, cyclin D (*CCND1*)⁸⁹, and the circadian clock gene *PER1*⁹⁰. While the Cavalli MB dataset does not include non-tumor controls, the Donson dataset showed that *USP2* expression was elevated compared to non-tumor brain. This was confirmed in the large meta-analysis of Weishaupt et al.⁴⁸ available in the R2 genomics site as the Swartling dataset, which identified *USP2* as the most significant differentially expressed gene in the five groups (non-tumor, Group 3, Group 4, SHH, Wnt). The role of *USP2* in the deubiquitination of clock proteins regulating the circadian rhythm of pathways is well documented^{91, 92}. *USP2* may function as an oncogene in breast and gastric cancer by inhibiting autophagy and this DUB has been proposed as a therapeutic target in breast cancer^{93, 94}. *USP2* expression was also differentially expressed according to age groups ($F = 13.73$, $p = 1.01\text{e-}08$). The age distribution for the four MB subgroups showed elevated *USP2* expression primarily in infants and children (**Fig. 10**) and high expression of *USP2* was associated with poor survival (**Table 4**). *USP2* may be a lucrative therapeutic target in patients with Group 3 MB.




Figure 9. Heatmap and cluster analysis of the top 12 differentially expressed DUB genes for each of the four MB subgroups compared to non-tumor brain (Note that due to overlap the total is less than 48). The Swartling dataset was used to identify top genes differing from non-tumor controls. The Cavalli dataset was used for the construction of the heatmap depicting the expression of these genes. Based on gene expression in the MB subgroups, the most significantly elevated DUBs for each group were: Group 3 – *USP2*; Group 4 – *USP20*; SHH – *EIF3H*; WNT – *USP5*. Group 3, N = 144; Group 4, N = 326; SHH, N = 223; Wnt, N = 70).

Table 4. Top ten differentially expressed DUB genes by MB subgroup compared to non-tumor group in the Swartling dataset.

Group 3 (N = 233)	DUB	p value vs non-tumor	Chromosome	Versus non-tumor group in the Swartling dataset
<i>USP46</i>	Usp	1.16e-57	4	Down
<i>USP2</i>	Usp	5.71e-53	11	Up
<i>PSMD14</i>	Jamm	4.25e-51	2	Up
<i>USP49</i>	Usp	1.34e-36	6	Up
<i>USP28</i>	Usp	2.41e-26	11	Down
<i>USP30</i>	Usp	1.29e-25	12	Up
<i>UCHL1</i>	Uch	1.72e-22	4	Down
<i>OTUD7A</i>	Otu	6.2e-22	15	Down
<i>USP44</i>	Usp	6.39e-22	12	Down
<i>COPS6</i>	Jamm	2.19E-21	7	Up
Group 4 (N = 530)				
<i>USP20</i>	Usp	8.96e-65	9	Up
<i>USP28</i>	Usp	2.28e-63	11	Down
<i>USP22</i>	Usp	1.35e-61	17	Up
<i>USP32</i>	Usp	1.21e-5	17	Up

<i>USP3</i>	Usp	2.98e-54	15	Down
<i>USP30</i>	Usp	2.19e-52	12	Up
<i>USP49</i>	Usp	1.49e-43	6	Up
<i>USP45</i>	Usp	9.56e-36	6	Down
<i>USP36</i>	Usp	7.95e-29	17	Up
<i>EIF3H</i>	Jamm	1.59e-27	8	Down
SHH (N = 405)				
<i>EIF3H</i>	Jamm	4.51e-135	8	Down
<i>USP2</i>	Usp	1.17e-88	11	Down
<i>USP20</i>	Usp	2.26e-69	9	Down
<i>CYLD</i>	Usp	7.13e-64	16	Down
<i>USP25</i>	Usp	4.63e-40	21	Down
<i>USP32</i>	Usp	4.97e-38	17	Down
<i>USP33</i>	Usp	5.42e-36	1	Down
<i>JOSD1</i>	Mjd	2.4e-30	22	Up
<i>USP11</i>	Usp	3.32e-28	X	Down
<i>USP13</i>	Usp	1.03e-26	3	Up
WNT (N = 118)				
<i>UCHL1</i>	Uch	2.14e-82	4	Down
<i>USP2</i>	Usp	3.18e-56	11	Down
<i>USP20</i>	Usp	6.88e-50	9	Down
<i>USP32</i>	Usp	2.23e-47	17	Down
<i>USP5</i>	Usp	1.19e-38	12	Up
<i>COPS6</i>	Jamm	2.5e-32	7	Up
<i>EIF3H</i>	Jamm	1.19e-29	8	Up
<i>OTUD7A</i>	Otu	1.48e-29	15	Down
<i>USP33</i>	Usp	1.38e-28	1	Down
<i>USP28</i>	Usp	6.05e-27	11	Down

Survival in Medulloblastoma Subgroups and DUB Expression

Overall survival in the Cavalli dataset, as determined by the R2 genomics platform, was best in the Wnt group, worst in Group 3, and intermediate in SHH and Group 4, confirming previously determined survival times⁴⁷. DUB genes that were significantly associated with survival ($p < 0.01$, for Kaplan-Meier curves) are listed in **Table 5** and includes DUB genes not differentially expressed between subgroups. DUB genes with the most significant Kaplan-Meier curves (high vs low) and hazard ratios included *VCPIP1*, *USP49*, and *USP2*. High expression of these genes was associated with worse survival (**Table 4**). While high expression of *VCPIP1* was associated with worse survival in the Cavalli dataset, expression of *VCPIP1* in none of the four MB groups was significantly higher than in non-tumor tissues in the Swartling dataset. High expression of *USP49* was observed in infants

and young children in Groups 3 and 4, whereas high expression of *USP2* was primarily observed in infants and young children in Group 3 (Fig. 10).

Table 5. DUB gene expression and medulloblastoma survival data (Cavalli dataset).

DUB	DUB family	Chromosome	Chi square Kaplan Meier	<i>p</i> value	Hazard Ratio	<i>p</i> value for hazard ratio	Better survival
<i>VCPIP1</i>	Otu	8	28.14	1.13e-07	1.9	1.10E-05	Low
<i>USP49</i>	Usp	6	26.73	2.34e-07	1.9	1.30E-05	Low
<i>USP2</i>	Usp	11	21.82	2.99e-06	1.3	3.50E-05	Low
<i>USP51</i>	Usp	X	19.36	1.08e-05	0.44	1.00E-04	High
<i>STAMBPL1</i>	Jamm	10	16.70	4.37e-05	0.73	3.10E-04	High
<i>PSMD14</i>	Jamm	2	18.05	2.16e-05	1.4	4.20E-04	Low
<i>ZRANB1</i>	Otu	10	17.11	3.52e-05	0.54	1.00E-03	High
<i>OTUD3</i>	Otu	1	18.76	1.48e-05	2.4	1.30E-03	Low
<i>PRPF8</i>	Jamm	17	18.77	1.47e-05	0.58	2.20E-03	High
<i>USP15</i>	Usp	12	16.42	5.06e-05	2	3.00E-03	Low
<i>USP45</i>	Usp	6	14.82	1.18e-04	1.5	3.90E-03	Low
<i>USP26</i>	Usp	X	22.77	1.82e-06	7.3	5.20E-03	Low
<i>USP36</i>	Usp	17	22.07	2.63e-06	2.2	5.50E-03	Low
<i>USPL1</i>	Usp	13	14.89	1.14e-04	2.1	5.80E-03	Low
<i>USP25</i>	Usp	21	12.36	4.39e-04	1.6	8.70E-03	Low
<i>EIF3H</i>	Jamm	8	13.23	2.75e-04	1.5	9.40E-03	Low
<i>COPS5</i>	Jamm	8	9.25	2.36e-03	1.9	9.90E-03	Low




Figure 10. Gene expression of *VCPIP1*, *USP49* and *USP2* in medulloblastoma by age and subgroups. Orange – Group 3, Gray – Group 4, Blue – SHH, Yellow – Wnt. Of these genes *USP2* expression was most specifically elevated in Group 3 MB infants and children compared to the other groups (Cavalli dataset) and compared to a non-tumor group (Swartling dataset).

Medulloblastoma DUBs and ERAD

Differential expression of several DUB genes (*USP13*, *USP14*, *USP25*, *USP19*, *OTUD2* (alias *YOD1*)) in the Cavalli dataset was associated with the GO category of *Regulation of ERAD pathway*. This list of genes includes three DUBs (*USP14*, *USP19*, *USP25*) shared with the list of differential expressed ERAD genes in glioma (Table 3). *USP25* was the only ERAD-associated DUB gene among the top ten DUB genes in the SHH MB group (Table 4). Our data implicate both *USP25* and *USP13*

with ERAD in the SHH group of MB (**Fig. 11**). In the Swartling dataset the expression of *USP25* was downregulated in the SHH group compared to non-tumor controls ($t = 14.37, p = 3.17\text{e-}41$), while the expression of *USP13* was elevated compared to non-tumor tissues ($t = 11.36, p = 1.41\text{e-}27$). Expression of *USP14*, but not *USP19* and *OTUD2*, was also reduced in the SHH group versus non-tumor tissues, but at a much lower level of significance ($t = 3.35, p = 8.64\text{e-}04$) (data not shown).




Figure 11. Differential expression of ERAD-associated DUBs in different medulloblastoma subgroups (Cavalli dataset). *USP25*, $F = 138.98, p = 9.08\text{e-}72$; *USP 13*, $F = 49.90, p = 1.93\text{e-}29$.

Medulloblastoma DUBs and the Immune Response

Five differentially expressed DUB genes were associated with the GO category of *Regulation of immune response* in the Cavalli dataset. This included DUB genes *CYLD* ($F = 141.44, p = 8.53\text{e-}73$), *PSMD14* ($F = 58.20, p = 7.15\text{e-}34$), *OTUD7A* ($F = 66.35, p = 4.14\text{e-}38$), *USP18* ($F = 37.27, p = 1.78\text{e-}22$), and *PSMD7* ($F = 16.56, p = 1.96\text{e-}10$). **Table 6** shows the genes that were significantly elevated or depressed compared to non-tumors samples in the Swartling dataset.

Table 6. DUBs and GO category of Regulation of immune response by MB group compared to non-tumor group of Swartling dataset (n = 291).

DUB	family	p value corrected FDR	Versus non-tumor group in Swartling dataset
Group 3 (n = 233)			
<i>PSMD14</i>	Jamm	8.74e-52	Up
<i>OTUD7A</i>	Otu	1.70e-22	Down
<i>TNFAIP3</i>	Otu	6.26e-10	Up
<i>CYLD</i>	Usp	3.54e-08	Down
Group 4 (n = 530)			
<i>PSMD14</i>	Jamm	2.23e-26	Up
<i>OTUD7A</i>	Otu	1.16e-13	Down
<i>CYLD</i>	Usp	7.04e-10	Up
<i>TNFAIP3</i>	Otu	5.67e-09	Up
SHH (n = 405)			
<i>CYLD</i>	Usp	1.95e-64	Down
<i>PSMD14</i>	Jamm	4.95e-09	Down

<i>TNFAIP3</i>	Otu	2.95e-08	Up
<i>PSMD7</i>	Jamm	5.19e-08	Up
Wnt (n = 118)			
<i>OTUD7A</i>	Otu	8.10e-30	Down
<i>PSMD7</i>	Jamm	3.89e-25	Up
<i>TNFAIP3</i>	Otu	2.40e-10	Down
<i>CYLD</i>	Usp	4.19e-04	Up
<i>PSMD14</i>	Jamm	8.99e-04	Up

CYLD is an inhibitor of the immune response, alters NF- κ B signaling, and affects the development and Th2 conversion of Treg cells^{86, 87, 95}. PSMD14 and PSMD7 are DUB components of the proteasome and PSMD14 is a druggable target that specifically deubiquitinates at K63 and suppresses autophagy by affecting vesicular retrograde transport from the Golgi to the ER^{96, 97}. OTUD7A contributes to neuronal development^{62, 63} and USP18 regulates the immune response by binding to the interferon receptor IFNAR2⁶⁷.

Medulloblastoma DUBs and DNA Damage Repair

Twelve of the 99 DUB genes were identified as differentially expressed in MB compared to non-tumor tissue ($p < 0.0001$) for the GO category of *DNA repair* in the Swartling dataset including *USP1*, *OTUB1*, *UCHL5*, *USP7*, and *PSMD14* (aka *POH1*) (**Table 7**). The DUB proteins USP1, OTUB1, UCHL5, USP7, and PSMD14 were reported to contribute to double strand break repair, USP1 to Fanconi anemia pathway, USP1 and USP7 to translesion repair, USP7 and USP47 to base excision repair, and USP7 and USP45 to nucleotide excision repair⁶⁸. In addition, the USP28 protein was also found to contribute to the DNA damage response⁹⁸. A highly significant reduction of *USP28* expression in Group 3, Group 4, and Wnt MB groups (**Table 7**) may point to an impaired DNA damage response in these MB groups. *PSMD14* was the most significantly upregulated DUB gene in Group 3 MB (**Table 7**)⁹⁹. A subtype-specific analysis revealed that *PSMD14* over-expression was limited to selected subtypes of Group 3 (Group 3 beta and gamma) and Group 4 (Group 4 alpha).

Table 7. DUBs and GO category of DNA repair in MB groups compared to non-tumor group.

DUB	family	<i>p</i> value vs NT group Swartling	Versus non-tumor group in Swartling dataset
Group 3 vs NT			
<i>PSMD14</i>	Jamm	2.27e-51	Up
<i>USP28</i>	Usp	1.07e-26	Down
<i>COPS6</i>	Jamm	1.30e-21	Up
<i>USP47</i>	Usp	3.96e-15	Down
<i>UCHL5</i>	Uch	6.12e-14	Up
<i>COPS5</i>	Jamm	1.61e-10	Up
<i>USP1</i>	Usp	2.53e-06	Up
<i>OTUB1</i>	Otu	3.33e-05	Down
Group 4 vs NT			

<i>Usp28</i>	Usp	8.12E-64	Down
<i>USP3</i>	Usp	1.33E-54	Down
<i>USP45</i>	Usp	4.54E-36	Down
<i>PSMD14</i>	Jamm	1.45E-26	Up
<i>COPS6</i>	Jamm	3.10E-24	Up
<i>USP1</i>	Usp	1.48E-16	Up
<i>OTUB1</i>	Otu	1.67E-14	Down
<i>USP7</i>	Usp	2.65E-12	Up
<i>COPS5</i>	Jamm	4.01E-06	Down
<i>USP47</i>	Usp	2.16E-04	Down
<i>UCHL5</i>	Uch	2.11E-03	Up
SHH vs NT			
<i>USP10</i>	Usp	2.21E-15	Up
<i>PSMD14</i>	Jamm	8.58E-09	Down
<i>COPS5</i>	Jamm	1.16E-08	Up
<i>USP45</i>	Usp	3.60E-07	Down
<i>UCHL5</i>	Uch	1.30E-06	Down
<i>USP3</i>	Usp	5.90E-06	Down
<i>COPS6</i>	Jamm	5.98E-06	Down
<i>USP1</i>	Usp	6.06E-06	Up
<i>USP47</i>	Usp	6.68E-04	Down
<i>USP7</i>	Usp	1.71E-03	Up
WNT vs NT			
<i>COPS6</i>	Jamm	2.67E-32	Up
<i>USP28</i>	Usp	5.39E-27	Down
<i>USP3</i>	Usp	3.53E-25	Down
<i>USP45</i>	Usp	2.61E-22	Down
<i>UCHL5</i>	Usp	4.72E-14	Down
<i>USP10</i>	Usp	7.73E-11	Up
<i>COPS5</i>	Jamm	1.02E-03	Up
<i>PSMD14</i>	Jamm	1.46E-03	Up
<i>OTUB1</i>	Otu	2.89E-03	Up
<i>USP1</i>	Usp	4.55E-03	Up

DUBs in Neuroblastoma (Fischer Dataset)

The dataset of Fischer on NBT allowed the examination of DUB genes in patients with various treatments. Intensive chemotherapy of NBT was associated with increased expression of selected DUB genes and a decrease in several other DUB members compared to the observation group. Intriguingly, limited chemotherapy or surgery had no significant effect on the expression of DUB genes compared to observation group alone (**Fig. 12**).




Figure 12. Treatment effects on DUB gene expression in Neuroblastoma. Intensive chemotherapy (ct) (N = 114), intermediate ct (N = 30), limited ct (N = 18), observation (no treatment control) (N =23), surgery (N = 43).

Patients receiving intensive chemotherapy of their NBT showed significantly reduced tumor tissue expression of *USP24*, *USP34*, *MINDY2*, *USP8*, *JOSD1*, *USP52*, and *USP12* when compared to the observation group. The most significant differences in DUB expression between limited and intensive chemotherapy included *USP24*, *JOSD1*, and *MINDY2* (**Fig. 13**). Notably, there were many other genes in the Fischer dataset that showed differential expression between the limited and intensive chemotherapy groups, the most significant of them being *MDGA1* ($F = 128.15$, $p = 4.24e-21$) with approximately 4-fold difference. *MDGA1* is expressed mainly in neurons and astrocytes of the brain.




Figure 13. DUB expression in limited vs intensive chemotherapy of neuroblastoma from the Fischer dataset. Limited chemotherapy (ct), N = 18, intermediate ct, N = 30, intensive ct, N = 114. USP 24, F = 21.10, $p = 7.44\text{e-}09$; JOSD1, F = 18.44, $p = 6.26\text{e-}08$; MINDY2, F = 21.61, $p = 4.99\text{e-}09$. *significantly different from limited ct group at $p < 0.001$ by t-test.

Discussion

The complex functional roles of DUBs in tumor biology is gradually emerging¹⁰⁰. Here we present a comprehensive gene expression profiling of 99 DUB family members in six different brain tumor entities that span different molecular subtypes and age groups. We also included gene expression data from different treatment groups of NBT, the most common extracranial sympathetic nervous system tumor in childhood, to better understand the emerging role of deubiquitinases in pediatric and adult CNS tumors. While we observed pronounced gene expression changes for several DUBs, for brevity, we will only discuss those selected DUB members with highest differential expression. Wherever possible, we have focused on known brain-related functions for these DUBs, with a particular emphasis on clinically relevant pathomechanisms, such as the ERAD pathway, immune system, and DNA damage repair.

GBM displayed a distinct downregulation of *USP46* and *ZRANB1*. Ubiquitously expressed throughout the mammalian brain, *USP46* is involved in the formation of synapses and neuronal morphogenesis by regulating both excitatory and inhibitory synaptic transmission¹⁰¹. By deubiquitinating K63 ubiquitinated glutaminergic AMPARs (α -amino-3-hydroxy-5methyl-4-isoxazolepropionic acid) receptors GluA1 and GluA2, which are considered to mediate most of the excitatory synaptic transmission in the brain, *USP46* upregulates the intracellular trafficking, cell surface density, and signal intensity of AMPARs^{101, 102}. These receptors are critical for perivascular brain invasion, promote plasticity and growth of GBM and coincide with poor prognosis¹⁰³⁻¹⁰⁵. *USP46* also interferes with the neuronal activity-dependent ubiquitination and trafficking of GABA_A receptors. Loss of *USP46* coincides with reduced expression of glutamic acid decarboxylase (*GAD67*) which synthesizes GABA¹⁰⁶. Recently, higher expression of the non-coding (nc)RNA *USP46-AS1* has been linked to increased overall survival in glioma¹⁰⁷. It is tempting to speculate that the marked

reduction in USP46 gene expression in GBM, but not AS, coincides with the acquisition of altered receptor density in the plasma membrane and synaptic activity during dedifferentiation from high-grade AS to GBM. GABA_A receptor activity was reported to inhibit glioma growth and lowest levels of GABA_A receptors were reported in GBM compared to lower grade glioma^{108, 109}.

While the role of ZRANB1 (zinc finger RANBP2-type containing 1, TRABID) in glioma is still unclear, it is likely multifactorial in nature. In breast cancer, this K29- and K33-specific DUB binds, deubiquitinates, and stabilizes enhancer of zeste homologue (EZH2) catalytic component of the gene silencing Polycomb repressive complex 2 (PRC2) to promote growth, resulting in poor prognosis⁵¹. USP1 in glioma¹¹⁰, as well as USP7 and USP34, also converge on EZH2 to promote tumorigenesis¹¹¹. Tight regulation of ZRANB1 expression is critical in glioma. Reduced expression of ZRANB1 may confer a survival advantage to GBM by reducing UPR through the recruitment of p62 to K33-ubiquitinated protein aggregates for autophagic removal¹¹². However, in solid tumors lower ZRANB1 levels coincide with epigenetic regulation that promotes interferon and inflammatory immune cell responses in the tumor microenvironment¹¹³⁻¹¹⁵. Lower ZRANB1 levels also attenuate deubiquitination of K29-linked polyubiquitinated repair factor 53BP1. Proteasomal removal of this DNA repair factor mitigates genomic instability by preventing 53BP1 from blocking homologous recombination repair at double strand DNA breaks¹¹⁶. Further studies are needed to establish the role of ZRANB1 in GBM.

Selected GBM, EPN, CPh, and MB subtypes showed distinct expression of specific DUB genes. Among 10 differentially expressed DUBs in the three GBM subtypes, only *TNFAIP3*, aka A20, was upregulated in mesenchymal GBM. Possessing both DUB and E3-ligase activities^{117, 118}, *TNFAIP3* is an important player in a diverse array of diseases¹¹⁹ and a key negative regulator of NFκB signaling downstream of TNF receptors, interleukin 1 receptor (IL-1R), pathogen recognition receptors (PRRs), NOD-like receptors (NLRs), T- and B-cell receptors, and CD40^{120, 121}. *TNFAIP3* regulates glioma stem cell survival, increases resistance to alkylating agents, and is considered a poor prognostic marker in GBM^{122, 123}. While *TNFAIP3* upregulation was a unique mesenchymal feature among GBM subtypes, DUB genes significantly associated with immune cell functions were identified in other GBM subtypes, the St_se subgroup of EPN, MB, and in CPh. This included *TNFAIP3*, *CYLD* (*Cylindromatosis*), another negative regulator of NF-κB signaling⁸⁷, and the critical neurodevelopmental factor and putative tumor suppressor *OTUD7A/Cezanne-2*⁶³. These data suggest a redundant role for several DUBs in targeting NF-κB signaling as a mechanism to regulate inflammatory and immune responses in intra- and extracranial nervous system brain tumors.

Among the four MB subgroups, we identified USP2 to be selectively upregulated primarily in infants and children within Group 3 MB (**Fig. 9**). Group 3 MB frequently have elevated MYC levels due to MYC overexpression or MYC gene amplifications and these patients have the worst prognosis of all MB groups with less than 50% survival^{124, 125}. In the Cavalli dataset, MYC expression was elevated most in the Group 3 gamma subtype. As may be expected, USP2 DUB functions target a wide range of interconnected pathways in a tissue-specific manner¹²⁶. Relevant USP2 functions in tumorigenesis target the metabolic (e.g., fatty acids) and p53 pathways, EMT, cell cycle control, and maintenance of genome stability¹²⁶. High USP2 levels resulted in the downregulation of several miRs, including MYC-targeting miR-34b/c, which resulted in deubiquitination of MDM2 and elevated MYC levels with subsequent p53 inactivation in prostate cancer cells¹²⁷. Hence, it is conceivable that higher USP2 expression may contribute to higher MYC protein levels in Group 3 MB patients.

Emerging research is starting to unravel the complex and clinically relevant relationships between UPR, ER and DNA stress signaling, chronic inflammation, and immune responses in primary brain tumors and their microenvironment¹²⁸⁻¹³¹. We identified a selected group of DUBs (USP13, USP14, USP19, USP25, OTUD2/ YOD1) associated with the *Regulation of ERAD pathway* across several adult and pediatric primary brain tumors (GBM, EPN, CPh, MB). A recent TCGA-based gene expression profiling interactive analysis (GEPIA; <http://gepia.cancer-pku.cn/>) of low-grade glioma and GBM identified lower expression of all but one (USP25) of these USP DUB members in GBM¹³². There was a strong correlation for higher expression of USP14 and worse prognosis in GBM patients¹³². In addition to its roles at the ER⁵⁸, USP14 (and UCH37) engage in polyubiquitin

chain trimming which can delay proteasomal degradation by weakening the affinity of ubiquitin chains with ubiquitin-binding receptors at the proteasome¹³³. Hence, USP14 has been targeted with a small molecule inhibitor¹³⁴ or selected USP14 aptamers¹³⁵ to enhance proteasomal activity and degradation of proteotoxicity. Although USP14 downregulation in several tumor types was shown to reduce tumor burden in mice, data are lacking for brain tumors^{136, 137}. OTUD2/ YOD1 is another DUB with regulator functions in the ERAD pathway and linked to injury-induced ER stress responses^{138, 139}. This includes a regulatory role of the inflammatory cytokine IL1 and p62 NFkB signaling axis through interaction with the E3 ligase TRAF6¹⁴⁰, which may contribute to OTUD2/ YOD1 deubiquitinating activity in attenuating neurogenic proteotoxicity¹⁴¹. In glioma, OTUD2/ YOD1 has been identified as a target of miR-190a-3p. Blocking miR-190a-3p or the overexpression of its target OTUD2/ YOD1 attenuated the proliferation and migration of glioma cells¹⁴². While the underlying mechanism is currently unknown, YAP and TAZ, the transcriptional coactivators and effectors of the Hippo signaling pathway, have been identified as downstream targets of an miR21-OTUD2-YAP/ TAZ axis in hepatocellular carcinoma¹⁴³, thus, potentially linking OTUD2/ YOD1 to glioma stem cell maintenance and proliferation¹⁴⁴.

Among the selected DUBs significantly linked to the DNA damage repair pathway, the glioma and MB data sets shared several DUBs, including *USP1*, *USP47*, *UCHL5*, *OTUD1*, which cover five major DNA damage repair pathways (BER, NER, FA, TLS, DSB)⁶⁸. USP1 targets FANCD2/FANCI to regulate the Fanconi anemia pathway (FA)¹⁴⁵ and, together with USP7 targets translesional DNA repair (TLS)^{146, 147}. USP7, a DDR-associated DUB exclusively altered in MB, and USP47 target the base excision repair pathway (BER)^{148, 149}, while USP7 and USP45 have regulate roles in nucleotide excision repair (NER)^{150, 151}. *UCHL5* and *OTUD1* were reported to increase or decrease double strand break repair (DSB), respectively^{152, 153}. Expressed among the top genes in group 3 MB and highly significantly associated with poor survival in MB groups 3 and 4 (**Tables 4+5**), *PSMD14* (aka *POH1*) was also significantly associated with immune responses and DNA repair, particularly in MB groups 3 and 4 (**Tables 6+7**). *PSMD14* was shown to fortify tumor cells against DNA damaging drugs by promoting a switch from non-homologous end-joining to homologous recombination^{154, 155}. This identifies proteasomal *PSMD14* as a key DUB in regulating ubiquitin conjugation in response to DNA damage and demonstrates the intricate relationships between the proteasome and DNA damage responses.

Changes in DUB expression also occur during treatment of extracranial NBT sympathetic nervous tumors. Our analysis of a data set from NBT undergoing different treatment options identified significantly reduced expression of seven (*USP24*, *USP34*, *MINDY2*, *USP8*, *JOSD1*, *USP52*, *USP12*) DUBs in treated versus non-treated NBT group. Intriguingly, *USP24*, *JOSD1*, and *MINDY2* showed the most significant downregulation during intensive versus limited chemotherapy (**Fig. 12**). *USP24* has recently been identified as a novel tumor suppressor in NBT that targets collapsin response mediator protein 2 (CRMP2), which promotes axon growth, guidance, and neuronal polarity but also affects T cell polarization and migration^{156, 157}. Deubiquitination of CRMP2 by *USP24* ensured proper spindle pole assembly and block chromosomal instability and aneuploidy observed upon *USP24* knockdown in NBT¹⁵⁸. A glimpse into possible additional cellular strategies in response to intensive treatment regimes in NBT cells comes from findings that *USP24* downregulation increases autophagy flux in cells¹⁵⁹. The biological roles of Machado-Joseph DUB member *JOSD1* are complex²³. While data on *JOSD1* in NBT are lacking, *JOSD1* can deubiquitinate and stabilize Snail protein to promote EMT and tissue invasion of lung cancer cells¹⁶⁰. A small molecule inhibitor of *JOSD1* was shown to induce cell death of JAK2-V617F-positive primary acute myeloid leukemia (AML) cells¹⁶¹. Downregulation of *JOSD1* in treated NBT may also affect regulatory mechanisms of interferon-1 mediated inflammatory cytokine responses¹⁶². The role of evolutionarily conserved *MINDY1/2* family of DUBs in brain tumors is currently unknown. However, *MINDY1* DUB activity promotes the proliferation of bladder cancer cells by stabilizing *MINDY1* interaction partner YAP protein and critical transcriptional regulator of the Hippo pathway. YAP overexpression in *MINDY1* depleted cells was able to rescue this proliferation¹⁶³. In human breast cancer cells, *MINDY1* stabilized estrogen receptor alpha (ERa) and promoted ERa mediated proliferation¹⁶⁴.

In conclusion, the role of DUBs as relevant modulators of tumor relevant cellular and immunomodulatory pathways in brain tumors is evolving. Selective DUB targeting strategies may provide important synergistic therapeutic potential in the future.

Author Contributions: Conceptualization, TK and JV; methodology JV; formal analysis JV; data curation JV; writing – original draft preparation TK and JV; writing – review and editing TK, SHK, SEL, JV; visualization JV, TK; project administration JV. All authors have read and agreed to the final version of the manuscript.

Funding: TK is grateful to the Natural Sciences and Engineering Research Council of Canada (NSERC) for funding.

Data Availability Statement: The data referred to in this manuscript are publicly available at the R2 Genomics Analysis and Visualization Platform (<http://r2.amc.nl>) and at the NIH GEO database and are available on reasonable request from the first author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Gao, T.; Liu, Z.; Wang, Y.; Cheng, H.; Yang, Q.; Guo, A.; Ren, J.; Xue, Y. UUCD: a family-based database of ubiquitin and ubiquitin-like conjugation. *Nucleic Acids Res* **2013**, *41* (Database issue), D445-451. DOI: 10.1093/nar/gks1103 From NLM Medline.
2. van der Veen, A. G.; Ploegh, H. L. Ubiquitin-like proteins. *Annu Rev Biochem* **2012**, *81*, 323-357. DOI: 10.1146/annurev-biochem-093010-153308 From NLM Medline.
3. Varshavsky, A. The Ubiquitin System, Autophagy, and Regulated Protein Degradation. *Annu Rev Biochem* **2017**, *86*, 123-128. DOI: 10.1146/annurev-biochem-061516-044859 From NLM Medline.
4. Dikic, I.; Schulman, B. A. An expanded lexicon for the ubiquitin code. *Nat Rev Mol Cell Biol* **2023**, *24* (4), 273-287. DOI: 10.1038/s41580-022-00543-1 From NLM Medline.
5. Swatek, K. N.; Komander, D. Ubiquitin modifications. *Cell Res* **2016**, *26* (4), 399-422. DOI: 10.1038/cr.2016.39 From NLM Medline.
6. Tracz, M.; Bialek, W. Beyond K48 and K63: non-canonical protein ubiquitination. *Cell Mol Biol Lett* **2021**, *26* (1), 1. DOI: 10.1186/s11658-020-00245-6 From NLM Medline.
7. Jacobson, A. D.; Zhang, N. Y.; Xu, P.; Han, K. J.; Noone, S.; Peng, J.; Liu, C. W. The lysine 48 and lysine 63 ubiquitin conjugates are processed differently by the 26 S proteasome. *J Biol Chem* **2009**, *284* (51), 35485-35494. DOI: 10.1074/jbc.M109.052928 From NLM Medline.
8. Kwon, Y. T.; Ciechanover, A. The Ubiquitin Code in the Ubiquitin-Proteasome System and Autophagy. *Trends Biochem Sci* **2017**, *42* (11), 873-886. DOI: 10.1016/j.tibs.2017.09.002 From NLM Medline.
9. Dosa, A.; Csizmadia, T. The role of K63-linked polyubiquitin in several types of autophagy. *Biol Futur* **2022**, *73* (2), 137-148. DOI: 10.1007/s42977-022-00117-4 From NLM Medline.
10. Liu, Z.; Gong, Z.; Jiang, W. X.; Yang, J.; Zhu, W. K.; Guo, D. C.; Zhang, W. P.; Liu, M. L.; Tang, C. Lys63-linked ubiquitin chain adopts multiple conformational states for specific target recognition. *Elife* **2015**, *4*. DOI: 10.7554/eLife.05767 From NLM Medline.
11. Suresh, H. G.; Pascoe, N.; Andrews, B. The structure and function of deubiquitinases: lessons from budding yeast. *Open Biol* **2020**, *10* (10), 200279. DOI: 10.1098/rsob.200279 From NLM Medline.
12. Mevissen, T. E. T.; Komander, D. Mechanisms of Deubiquitinase Specificity and Regulation. *Annu Rev Biochem* **2017**, *86*, 159-192. DOI: 10.1146/annurev-biochem-061516-044916 From NLM Medline.
13. Komander, D.; Clague, M. J.; Urbe, S. Breaking the chains: structure and function of the deubiquitinases. *Nat Rev Mol Cell Biol* **2009**, *10* (8), 550-563. DOI: 10.1038/nrm2731 From NLM Medline.
14. Lange, S. M.; Armstrong, L. A.; Kulathu, Y. Deubiquitinases: From mechanisms to their inhibition by small molecules. *Mol Cell* **2022**, *82* (1), 15-29. DOI: 10.1016/j.molcel.2021.10.027 From NLM Medline.
15. Deng, L.; Meng, T.; Chen, L.; Wei, W.; Wang, P. The role of ubiquitination in tumorigenesis and targeted drug discovery. *Signal Transduct Target Ther* **2020**, *5* (1), 11. DOI: 10.1038/s41392-020-0107-0 From NLM Medline.
16. Davis, M. I.; Simeonov, A. Ubiquitin-Specific Proteases as Druggable Targets. *Drug Target Rev* **2015**, *2* (3), 60-64. From NLM PubMed-not-MEDLINE.
17. Rong, C.; Zhou, R.; Wan, S.; Su, D.; Wang, S. L.; Hess, J. Ubiquitin Carboxyl-Terminal Hydrolases and Human Malignancies: The Novel Prognostic and Therapeutic Implications for Head and Neck Cancer. *Front Oncol* **2020**, *10*, 592501. DOI: 10.3389/fonc.2020.592501 From NLM PubMed-not-MEDLINE.
18. Johnston, S. C.; Riddle, S. M.; Cohen, R. E.; Hill, C. P. Structural basis for the specificity of ubiquitin C-terminal hydrolases. *EMBO J* **1999**, *18* (14), 3877-3887. DOI: 10.1093/emboj/18.14.3877 From NLM Medline.

19. Larsen, C. N.; Price, J. S.; Wilkinson, K. D. Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. *Biochemistry* **1996**, *35* (21), 6735-6744. DOI: 10.1021/bi960099f From NLM Medline.
20. Makarova, K. S.; Aravind, L.; Koonin, E. V. A novel superfamily of predicted cysteine proteases from eukaryotes, viruses and Chlamydia pneumoniae. *Trends Biochem Sci* **2000**, *25* (2), 50-52. DOI: 10.1016/s0968-0004(99)01530-3 From NLM Medline.
21. Du, J.; Fu, L.; Sui, Y.; Zhang, L. The function and regulation of OTU deubiquitinases. *Front Med* **2020**, *14* (5), 542-563. DOI: 10.1007/s11684-019-0734-4 From NLM Medline.
22. Schluter, D.; Schulze-Niemand, E.; Stein, M.; Naumann, M. Ovarian tumor domain proteases in pathogen infection. *Trends Microbiol* **2022**, *30* (1), 22-33. DOI: 10.1016/j.tim.2021.04.002 From NLM Medline.
23. Zeng, C.; Zhao, C.; Ge, F.; Li, Y.; Cao, J.; Ying, M.; Lu, J.; He, Q.; Yang, B.; Dai, X.; et al. Machado-Joseph Deubiquitinases: From Cellular Functions to Potential Therapy Targets. *Front Pharmacol* **2020**, *11*, 1311. DOI: 10.3389/fphar.2020.01311 From NLM PubMed-not-MEDLINE.
24. Patterson-Fortin, J.; Shao, G.; Bretscher, H.; Messick, T. E.; Greenberg, R. A. Differential regulation of JAMM domain deubiquitinating enzyme activity within the RAP80 complex. *J Biol Chem* **2010**, *285* (40), 30971-30981. DOI: 10.1074/jbc.M110.135319 From NLM Medline.
25. Pan, X.; Wu, S.; Wei, W.; Chen, Z.; Wu, Y.; Gong, K. Structural and Functional Basis of JAMM Deubiquitinating Enzymes in Disease. *Biomolecules* **2022**, *12* (7). DOI: 10.3390/biom12070910 From NLM Medline.
26. Dubiel, W.; Chaithongyot, S.; Dubiel, D.; Naumann, M. The COP9 Signalosome: A Multi-DUB Complex. *Biomolecules* **2020**, *10* (7). DOI: 10.3390/biom10071082 From NLM Medline.
27. Abdul Rehman, S. A.; Kristariyanto, Y. A.; Choi, S. Y.; Nkosi, P. J.; Weidlich, S.; Labib, K.; Hofmann, K.; Kulathu, Y. MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes. *Mol Cell* **2016**, *63* (1), 146-155. DOI: 10.1016/j.molcel.2016.05.009 From NLM Medline.
28. Hickey, C. M.; Wilson, N. R.; Hochstrasser, M. Function and regulation of SUMO proteases. *Nat Rev Mol Cell Biol* **2012**, *13* (12), 755-766. DOI: 10.1038/nrm3478 From NLM Medline.
29. Tokarz, P.; Wozniak, K. SENP Proteases as Potential Targets for Cancer Therapy. *Cancers (Basel)* **2021**, *13* (9). DOI: 10.3390/cancers13092059 From NLM PubMed-not-MEDLINE.
30. Mendoza, H. M.; Shen, L. N.; Botting, C.; Lewis, A.; Chen, J.; Ink, B.; Hay, R. T. NEDP1, a highly conserved cysteine protease that deNEDDylates Cullins. *J Biol Chem* **2003**, *278* (28), 25637-25643. DOI: 10.1074/jbc.M212948200 From NLM Medline.
31. Qu, J.; Zou, T.; Lin, Z. The Roles of the Ubiquitin-Proteasome System in the Endoplasmic Reticulum Stress Pathway. *Int J Mol Sci* **2021**, *22* (4). DOI: 10.3390/ijms22041526 From NLM Medline.
32. Shibata, Y.; Voeltz, G. K.; Rapoport, T. A. Rough sheets and smooth tubules. *Cell* **2006**, *126* (3), 435-439. DOI: 10.1016/j.cell.2006.07.019 From NLM Medline.
33. Schwarz, D. S.; Blower, M. D. The endoplasmic reticulum: structure, function and response to cellular signaling. *Cell Mol Life Sci* **2016**, *73* (1), 79-94. DOI: 10.1007/s00018-015-2052-6 From NLM Medline.
34. Almanza, A.; Carlesso, A.; Chintha, C.; Creedican, S.; Doultisinos, D.; Leuzzi, B.; Luis, A.; McCarthy, N.; Montibeller, L.; More, S.; et al. Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications. *FEBS J* **2019**, *286* (2), 241-278. DOI: 10.1111/febs.14608 From NLM Medline.
35. He, B. Viruses, endoplasmic reticulum stress, and interferon responses. *Cell Death Differ* **2006**, *13* (3), 393-403. DOI: 10.1038/sj.cdd.4401833 From NLM Medline.
36. Shen, J.; Chen, X.; Hendershot, L.; Prywes, R. ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. *Dev Cell* **2002**, *3* (1), 99-111. DOI: 10.1016/s1534-5807(02)00203-4 From NLM Medline.
37. Bertolotti, A.; Zhang, Y.; Hendershot, L. M.; Harding, H. P.; Ron, D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. *Nat Cell Biol* **2000**, *2* (6), 326-332. DOI: 10.1038/35014014 From NLM Medline.
38. Madden, E.; Logue, S. E.; Healy, S. J.; Manie, S.; Samali, A. The role of the unfolded protein response in cancer progression: From oncogenesis to chemoresistance. *Biol Cell* **2019**, *111* (1), 1-17. DOI: 10.1111/boc.201800050 From NLM Medline.
39. Park, J.; Cho, J.; Song, E. J. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. *Arch Pharm Res* **2020**, *43* (11), 1144-1161. DOI: 10.1007/s12272-020-01281-8 From NLM Medline.
40. Jurkovicova, D.; Neophytou, C. M.; Gasparovic, A. C.; Goncalves, A. C. DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. *Int J Mol Sci* **2022**, *23* (23). DOI: 10.3390/ijms232314672 From NLM Medline.

41. Pilger, D.; Seymour, L. W.; Jackson, S. P. Interfaces between cellular responses to DNA damage and cancer immunotherapy. *Genes Dev* **2021**, *35* (9-10), 602-618. DOI: 10.1101/gad.348314.121 From NLM Medline.
42. Vriend, J.; Klonisch, T. Genes of the Ubiquitin Proteasome System Qualify as Differential Markers in Malignant Glioma of Astrocytic and Oligodendroglial Origin. *Cell Mol Neurobiol* **2023**, *43* (4), 1425-1452. DOI: 10.1007/s10571-022-01261-0 From NLM Medline.
43. Vriend, J.; Thanasupawat, T.; Sinha, N.; Klonisch, T. Ubiquitin Proteasome Gene Signatures in Ependymoma Molecular Subtypes. *Int J Mol Sci* **2022**, *23* (20). DOI: 10.3390/ijms232012330 From NLM Medline.
44. Maris, J. M.; Hogarty, M. D.; Bagatell, R.; Cohn, S. L. Neuroblastoma. *Lancet* **2007**, *369* (9579), 2106-2120. DOI: 10.1016/S0140-6736(07)60983-0 From NLM Medline.
45. Park, J. R.; Bagatell, R.; London, W. B.; Maris, J. M.; Cohn, S. L.; Mattay, K. K.; Hogarty, M.; Committee, C. O. G. N. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. *Pediatr Blood Cancer* **2013**, *60* (6), 985-993. DOI: 10.1002/pbc.24433 From NLM Medline.
46. Gravendeel, L. A.; Kouwenhoven, M. C.; Gevaert, O.; de Rooi, J. J.; Stubbs, A. P.; Duijm, J. E.; Daemen, A.; Bleeker, F. E.; Bralten, L. B.; Kloosterhof, N. K.; et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. *Cancer Res* **2009**, *69* (23), 9065-9072. DOI: 10.1158/0008-5472.CAN-09-2307 From NLM Medline.
47. Cavalli, F. M. G.; Remke, M.; Rampasek, L.; Peacock, J.; Shih, D. J. H.; Luu, B.; Garzia, L.; Torchia, J.; Nor, C.; Morrissy, A. S.; et al. Intertumoral Heterogeneity within Medulloblastoma Subgroups. *Cancer Cell* **2017**, *31* (6), 737-754 e736. DOI: 10.1016/j.ccell.2017.05.005 From NLM Medline.
48. Weishaupt, H.; Johansson, P.; Sundstrom, A.; Lubovac-Pilav, Z.; Olsson, B.; Nelander, S.; Swartling, F. J. Batch-normalization of cerebellar and medulloblastoma gene expression datasets utilizing empirically defined negative control genes. *Bioinformatics* **2019**, *35* (18), 3357-3364. DOI: 10.1093/bioinformatics/btz066 From NLM Medline.
49. Ackermann, S.; Cartolano, M.; Hero, B.; Welte, A.; Kahlert, Y.; Roderwieser, A.; Bartenhagen, C.; Walter, E.; Gecht, J.; Kerschke, L.; et al. A mechanistic classification of clinical phenotypes in neuroblastoma. *Science* **2018**, *362* (6419), 1165-1170. DOI: 10.1126/science.aat6768 From NLM Medline.
50. Seifert, M.; Schackert, G.; Temme, A.; Schrock, E.; Deutsch, A.; Klink, B. Molecular Characterization of Astrocytoma Progression Towards Secondary Glioblastomas Utilizing Patient-Matched Tumor Pairs. *Cancers (Basel)* **2020**, *12* (6). DOI: 10.3390/cancers12061696 From NLM PubMed-not-MEDLINE.
51. Zhang, P.; Xiao, Z.; Wang, S.; Zhang, M.; Wei, Y.; Hang, Q.; Kim, J.; Yao, F.; Rodriguez-Aguayo, C.; Ton, B. N.; et al. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. *Cell Rep* **2018**, *23* (3), 823-837. DOI: 10.1016/j.celrep.2018.03.078 From NLM Medline.
52. Duan, R.; Du, W.; Guo, W. EZH2: a novel target for cancer treatment. *J Hematol Oncol* **2020**, *13* (1), 104. DOI: 10.1186/s13045-020-00937-8 From NLM Medline.
53. Straining, R.; Eighmy, W. Tazemetostat: EZH2 Inhibitor. *J Adv Pract Oncol* **2022**, *13* (2), 158-163. DOI: 10.6004/jadpro.2022.13.2.7 From NLM PubMed-not-MEDLINE.
54. Fujisawa, H.; Reis, R. M.; Nakamura, M.; Colella, S.; Yonekawa, Y.; Kleihues, P.; Ohgaki, H. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. *Lab Invest* **2000**, *80* (1), 65-72. DOI: 10.1038/labinvest.3780009 From NLM Medline.
55. Balesaria, S.; Brock, C.; Bower, M.; Clark, J.; Nicholson, S. K.; Lewis, P.; de Sanctis, S.; Evans, H.; Peterson, D.; Mendoza, N.; et al. Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas. *Br J Cancer* **1999**, *81* (8), 1371-1377. DOI: 10.1038/sj.bjc.6693403 From NLM Medline.
56. Wiles, B.; Miao, M.; Coyne, E.; Larose, L.; Cybulsky, A. V.; Wing, S. S. USP19 deubiquitinating enzyme inhibits muscle cell differentiation by suppressing unfolded-protein response signaling. *Mol Biol Cell* **2015**, *26* (5), 913-923. DOI: 10.1091/mbc.E14-06-1129 From NLM Medline.
57. Harada, K.; Kato, M.; Nakamura, N. USP19-Mediated Deubiquitination Facilitates the Stabilization of HRD1 Ubiquitin Ligase. *Int J Mol Sci* **2016**, *17* (11). DOI: 10.3390/ijms17111829 From NLM Medline.
58. Nagai, A.; Kadowaki, H.; Maruyama, T.; Takeda, K.; Nishitoh, H.; Ichijo, H. USP14 inhibits ER-associated degradation via interaction with IRE1alpha. *Biochem Biophys Res Commun* **2009**, *379* (4), 995-1000. DOI: 10.1016/j.bbrc.2008.12.182 From NLM Medline.
59. Blount, J. R.; Burr, A. A.; Denuc, A.; Marfany, G.; Todi, S. V. Ubiquitin-specific protease 25 functions in Endoplasmic Reticulum-associated degradation. *PLoS One* **2012**, *7* (5), e36542. DOI: 10.1371/journal.pone.0036542 From NLM Medline.
60. Zhu, D.; Xu, R.; Huang, X.; Tang, Z.; Tian, Y.; Zhang, J.; Zheng, X. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. *Cell Death Differ* **2021**, *28* (6), 1773-1789. DOI: 10.1038/s41418-020-00700-z From NLM Medline.

61. Wu, Q.; Huang, Y.; Gu, L.; Chang, Z.; Li, G. M. OTUB1 stabilizes mismatch repair protein MSH2 by blocking ubiquitination. *J Biol Chem* **2021**, *296*, 100466. DOI: 10.1016/j.jbc.2021.100466 From NLM Medline.
62. Unda, B. K.; Chalil, L.; Yoon, S.; Kilpatrick, S.; Irwin, C.; Xing, S.; Murtaza, N.; Cheng, A.; Brown, C.; Afonso, A.; et al. Impaired OTUD7A-dependent Ankyrin regulation mediates neuronal dysfunction in mouse and human models of the 15q13.3 microdeletion syndrome. *Mol Psychiatry* **2023**, *28* (4), 1747-1769. DOI: 10.1038/s41380-022-01937-5 From NLM Medline.
63. Yin, J.; Chen, W.; Chao, E. S.; Soriano, S.; Wang, L.; Wang, W.; Cummock, S. E.; Tao, H.; Pang, K.; Liu, Z.; et al. Otud7a Knockout Mice Recapitulate Many Neurological Features of 15q13.3 Microdeletion Syndrome. *Am J Hum Genet* **2018**, *102* (2), 296-308. DOI: 10.1016/j.ajhg.2018.01.005 From NLM Medline.
64. Bonacci, T.; Emanuele, M. J. Dissenting degradation: Deubiquitinases in cell cycle and cancer. *Semin Cancer Biol* **2020**, *67* (Pt 2), 145-158. DOI: 10.1016/j.semcancer.2020.03.008 From NLM Medline.
65. Das, T.; Chen, Z.; Hendriks, R. W.; Kool, M. A20/Tumor Necrosis Factor alpha-Induced Protein 3 in Immune Cells Controls Development of Autoinflammation and Autoimmunity: Lessons from Mouse Models. *Front Immunol* **2018**, *9*, 104. DOI: 10.3389/fimmu.2018.00104 From NLM Medline.
66. Ando, M.; Sato, Y.; Takata, K.; Nomoto, J.; Nakamura, S.; Ohshima, K.; Takeuchi, T.; Orita, Y.; Kobayashi, Y.; Yoshino, T. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas. *PLoS One* **2013**, *8* (2), e56741. DOI: 10.1371/journal.pone.0056741 From NLM Medline.
67. Malakhova, O. A.; Kim, K. I.; Luo, J. K.; Zou, W.; Kumar, K. G.; Fuchs, S. Y.; Shuai, K.; Zhang, D. E. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. *EMBO J* **2006**, *25* (11), 2358-2367. DOI: 10.1038/sj.emboj.7601149 From NLM Medline.
68. Le, J.; Perez, E.; Nemzow, L.; Gong, F. Role of deubiquitinases in DNA damage response. *DNA Repair (Amst)* **2019**, *76*, 89-98. DOI: 10.1016/j.dnarep.2019.02.011 From NLM Medline.
69. Lai, K. P.; Chen, J.; Tse, W. K. F. Role of Deubiquitinases in Human Cancers: Potential Targeted Therapy. *Int J Mol Sci* **2020**, *21* (7). DOI: 10.3390/ijms21072548 From NLM Medline.
70. Nakamura, N.; Hirose, S. Regulation of mitochondrial morphology by USP30, a deubiquitinating enzyme present in the mitochondrial outer membrane. *Mol Biol Cell* **2008**, *19* (5), 1903-1911. DOI: 10.1091/mbc.e07-11-1103 From NLM Medline.
71. Wauer, T.; Swatek, K. N.; Wagstaff, J. L.; Gladkova, C.; Pruneda, J. N.; Michel, M. A.; Gersch, M.; Johnson, C. M.; Freund, S. M.; Komander, D. Ubiquitin Ser65 phosphorylation affects ubiquitin structure, chain assembly and hydrolysis. *EMBO J* **2015**, *34* (3), 307-325. DOI: 10.15252/embj.201489847 From NLM Medline.
72. Cunningham, C. N.; Baughman, J. M.; Phu, L.; Tea, J. S.; Yu, C.; Coons, M.; Kirkpatrick, D. S.; Bingol, B.; Corn, J. E. USP30 and parkin homeostatically regulate atypical ubiquitin chains on mitochondria. *Nat Cell Biol* **2015**, *17* (2), 160-169. DOI: 10.1038/ncb3097 From NLM Medline.
73. Bingol, B.; Tea, J. S.; Phu, L.; Reichelt, M.; Bakalarski, C. E.; Song, Q.; Foreman, O.; Kirkpatrick, D. S.; Sheng, M. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. *Nature* **2014**, *510* (7505), 370-375. DOI: 10.1038/nature13418 From NLM Medline.
74. Sato, Y.; Yoshikawa, A.; Yamagata, A.; Mimura, H.; Yamashita, M.; Ookata, K.; Nureki, O.; Iwai, K.; Komada, M.; Fukai, S. Structural basis for specific cleavage of Lys 63-linked polyubiquitin chains. *Nature* **2008**, *455* (7211), 358-362. DOI: 10.1038/nature07254 From NLM Medline.
75. Wang, D.; Xu, C.; Yang, W.; Chen, J.; Ou, Y.; Guan, Y.; Guan, J.; Liu, Y. E3 ligase RNF167 and deubiquitinase STAMBPL1 modulate mTOR and cancer progression. *Mol Cell* **2022**, *82* (4), 770-784 e779. DOI: 10.1016/j.molcel.2022.01.002 From NLM Medline.
76. Mahul-Mellier, A. L.; Pazarentzos, E.; Datler, C.; Iwasawa, R.; AbuAli, G.; Lin, B.; Grimm, S. Deubiquitinating protease USP2a targets RIP1 and TRAF2 to mediate cell death by TNF. *Cell Death Differ* **2012**, *19* (5), 891-899. DOI: 10.1038/cdd.2011.185 From NLM Medline.
77. Xu, G.; Tan, X.; Wang, H.; Sun, W.; Shi, Y.; Burlingame, S.; Gu, X.; Cao, G.; Zhang, T.; Qin, J.; et al. Ubiquitin-specific peptidase 21 inhibits tumor necrosis factor alpha-induced nuclear factor kappaB activation via binding to and deubiquitinating receptor-interacting protein 1. *J Biol Chem* **2010**, *285* (2), 969-978. DOI: 10.1074/jbc.M109.042689 From NLM Medline.
78. Goricke, F.; Vu, V.; Smith, L.; Scheib, U.; Bohm, R.; Akkili, N.; Wohlfahrt, G.; Weiske, J.; Bommer, U.; Brzezinka, K.; et al. Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21. *J Med Chem* **2023**, *66* (5), 3431-3447. DOI: 10.1021/acs.jmedchem.2c01933 From NLM Medline.
79. Pajtler, K. W.; Mack, S. C.; Ramaswamy, V.; Smith, C. A.; Witt, H.; Smith, A.; Hansford, J. R.; von Hoff, K.; Wright, K. D.; Hwang, E.; et al. The current consensus on the clinical management of intracranial

- ependymoma and its distinct molecular variants. *Acta Neuropathol* **2017**, 133 (1), 5-12. DOI: 10.1007/s00401-016-1643-0 From NLM Medline.
80. Hyrskyluoto, A.; Bruelle, C.; Lundh, S. H.; Do, H. T.; Kivinen, J.; Rappou, E.; Reijonen, S.; Waltimo, T.; Petersen, A.; Lindholm, D.; et al. Ubiquitin-specific protease-14 reduces cellular aggregates and protects against mutant huntingtin-induced cell degeneration: involvement of the proteasome and ER stress-activated kinase IRE1alpha. *Hum Mol Genet* **2014**, 23 (22), 5928-5939. DOI: 10.1093/hmg/ddu317 From NLM Medline.
 81. Giordano, M.; Roncagalli, R.; Bourdely, P.; Chasson, L.; Buferne, M.; Yamasaki, S.; Beyaert, R.; van Loo, G.; Auphan-Anezin, N.; Schmitt-Verhulst, A. M.; et al. The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. *Proc Natl Acad Sci U S A* **2014**, 111 (30), 11115-11120. DOI: 10.1073/pnas.1406259111 From NLM Medline.
 82. Momtazi, G.; Lambrecht, B. N.; Naranjo, J. R.; Schock, B. C. Regulators of A20 (TNFAIP3): new drug-able targets in inflammation. *Am J Physiol Lung Cell Mol Physiol* **2019**, 316 (3), L456-L469. DOI: 10.1152/ajplung.00335.2018 From NLM Medline.
 83. (83) van Bon, B. W. M.; Mefford, H. C.; de Vries, B. B. A.; Schaaf, C. P. 15q13.3 Recurrent Deletion. In *GeneReviews*((R)), Adam, M. P., Mirzaa, G. M., Pagon, R. A., Wallace, S. E., Bean, L. J. H., Gripp, K. W., Amemiya, A. Eds.; 1993.
 84. Uddin, M.; Unda, B. K.; Kwan, V.; Holzapfel, N. T.; White, S. H.; Chalil, L.; Woodbury-Smith, M.; Ho, K. S.; Harward, E.; Murtaza, N.; et al. OTUD7A Regulates Neurodevelopmental Phenotypes in the 15q13.3 Microdeletion Syndrome. *Am J Hum Genet* **2018**, 102 (2), 278-295. DOI: 10.1016/j.ajhg.2018.01.006 From NLM Medline.
 85. Lim, J. H.; Ha, U. H.; Woo, C. H.; Xu, H.; Li, J. D. CYLD is a crucial negative regulator of innate immune response in Escherichia coli pneumonia. *Cell Microbiol* **2008**, 10 (11), 2247-2256. DOI: 10.1111/j.1462-5822.2008.01204.x From NLM Medline.
 86. Deng, M.; Dai, W.; Yu, V. Z.; Tao, L.; Lung, M. L. Cylindromatosis Lysine 63 Deubiquitinase (CYLD) Regulates NF-kB Signaling Pathway and Modulates Fibroblast and Endothelial Cells Recruitment in Nasopharyngeal Carcinoma. *Cancers (Basel)* **2020**, 12 (7). DOI: 10.3390/cancers12071924 From NLM PubMed-not-MEDLINE.
 87. Sun, S. C. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. *Cell Death Differ* **2010**, 17 (1), 25-34. DOI: 10.1038/cdd.2009.43 From NLM Medline.
 88. Stevenson, L. F.; Sparks, A.; Allende-Vega, N.; Xirodimas, D. P.; Lane, D. P.; Saville, M. K. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. *EMBO J* **2007**, 26 (4), 976-986. DOI: 10.1038/sj.emboj.7601567 From NLM Medline.
 89. Shan, J.; Zhao, W.; Gu, W. Suppression of cancer cell growth by promoting cyclin D1 degradation. *Mol Cell* **2009**, 36 (3), 469-476. DOI: 10.1016/j.molcel.2009.10.018 From NLM Medline.
 90. Yang, Y.; Duguay, D.; Fahrenkrug, J.; Cermakian, N.; Wing, S. S. USP2 regulates the intracellular localization of PER1 and circadian gene expression. *J Biol Rhythms* **2014**, 29 (4), 243-256. DOI: 10.1177/0748730414544741 From NLM Medline.
 91. Scoma, H. D.; Humby, M.; Yadav, G.; Zhang, Q.; Fogerty, J.; Besharse, J. C. The de-ubiquitylating enzyme, USP2, is associated with the circadian clockwork and regulates its sensitivity to light. *PLoS One* **2011**, 6 (9), e25382. DOI: 10.1371/journal.pone.0025382 From NLM Medline.
 92. Stojkovic, K.; Wing, S. S.; Cermakian, N. A central role for ubiquitination within a circadian clock protein modification code. *Front Mol Neurosci* **2014**, 7, 69. DOI: 10.3389/fnmol.2014.00069 From NLM PubMed-not-MEDLINE.
 93. He, J.; Lee, H. J.; Saha, S.; Ruan, D.; Guo, H.; Chan, C. H. Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy. *Cell Death Dis* **2019**, 10 (4), 285. DOI: 10.1038/s41419-019-1512-6 From NLM Medline.
 94. Xiao, W.; Wang, J.; Wang, X.; Cai, S.; Guo, Y.; Ye, L.; Li, D.; Hu, A.; Jin, S.; Yuan, B.; et al. Therapeutic targeting of the USP2-E2F4 axis inhibits autophagic machinery essential for zinc homeostasis in cancer progression. *Autophagy* **2022**, 18 (11), 2615-2635. DOI: 10.1080/15548627.2022.2044651 From NLM Medline.
 95. Lee, J. H.; Zou, L.; Yang, R.; Han, J.; Wan, Q.; Zhang, X.; El Baghdady, S.; Roman, A.; Elly, C.; Jin, H. S.; et al. The deubiquitinase CYLD controls protective immunity against helminth infection by regulation of Treg cell plasticity. *J Allergy Clin Immunol* **2021**, 148 (1), 209-224 e209. DOI: 10.1016/j.jaci.2020.10.042 From NLM Medline.
 96. Bustamante, H. A.; Cereceda, K.; Gonzalez, A. E.; Valenzuela, G. E.; Cheuquemilla, Y.; Hernandez, S.; Arias-Munoz, E.; Cerda-Troncoso, C.; Bandau, S.; Soza, A.; et al. The Proteasomal Deubiquitinating Enzyme PSMD14 Regulates Macroautophagy by Controlling Golgi-to-ER Retrograde Transport. *Cells* **2020**, 9 (3). DOI: 10.3390/cells9030777 From NLM Medline.

97. Bustamante, H. A.; Albornoz, N.; Morselli, E.; Soza, A.; Burgos, P. V. Novel insights into the non-canonical roles of PSMD14/POH1/Rpn11 in proteostasis and in the modulation of cancer progression. *Cell Signal* **2023**, *101*, 110490. DOI: 10.1016/j.cellsig.2022.110490 From NLM Medline.
98. Zhang, D.; Zaugg, K.; Mak, T. W.; Elledge, S. J. A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. *Cell* **2006**, *126* (3), 529-542. DOI: 10.1016/j.cell.2006.06.039 From NLM Medline.
99. Jacq, X.; Kemp, M.; Martin, N. M.; Jackson, S. P. Deubiquitylating enzymes and DNA damage response pathways. *Cell Biochem Biophys* **2013**, *67* (1), 25-43. DOI: 10.1007/s12013-013-9635-3 From NLM Medline.
100. Liang, X. W.; Wang, S. Z.; Liu, B.; Chen, J. C.; Cao, Z.; Chu, F. R.; Lin, X.; Liu, H.; Wu, J. C. A review of deubiquitinases and their roles in tumorigenesis and development. *Front Bioeng Biotechnol* **2023**, *11*, 1204472. DOI: 10.3389/fbioe.2023.1204472 From NLM PubMed-not-MEDLINE.
101. Huo, Y.; Khatri, N.; Hou, Q.; Gilbert, J.; Wang, G.; Man, H. Y. The deubiquitinating enzyme USP46 regulates AMPA receptor ubiquitination and trafficking. *J Neurochem* **2015**, *134* (6), 1067-1080. DOI: 10.1111/jnc.13194 From NLM Medline.
102. Anggono, V.; Huganir, R. L. Regulation of AMPA receptor trafficking and synaptic plasticity. *Curr Opin Neurobiol* **2012**, *22* (3), 461-469. DOI: 10.1016/j.conb.2011.12.006 From NLM Medline.
103. Ishiuchi, S.; Tsuzuki, K.; Yoshida, Y.; Yamada, N.; Hagimura, N.; Okado, H.; Miwa, A.; Kurihara, H.; Nakazato, Y.; Tamura, M.; et al. Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. *Nat Med* **2002**, *8* (9), 971-978. DOI: 10.1038/nm746 From NLM Medline.
104. Piao, Y.; Lu, L.; de Groot, J. AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix. *Neuro Oncol* **2009**, *11* (3), 260-273. DOI: 10.1215/15228517-2008-094 From NLM Medline.
105. Krishna, S.; Choudhury, A.; Keough, M. B.; Seo, K.; Ni, L.; Kakaizada, S.; Lee, A.; Aabedi, A.; Popova, G.; Lipkin, B.; et al. Glioblastoma remodelling of human neural circuits decreases survival. *Nature* **2023**, *617* (7961), 599-607. DOI: 10.1038/s41586-023-06036-1 From NLM Medline.
106. Tomida, S.; Mamiya, T.; Sakamaki, H.; Miura, M.; Aosaki, T.; Masuda, M.; Niwa, M.; Kameyama, T.; Kobayashi, J.; Iwaki, Y.; et al. Usp46 is a quantitative trait gene regulating mouse immobile behavior in the tail suspension and forced swimming tests. *Nat Genet* **2009**, *41* (6), 688-695. DOI: 10.1038/ng.344 From NLM Medline.
107. Xian, J.; Zhang, Q.; Guo, X.; Liang, X.; Liu, X.; Feng, Y. A prognostic signature based on three non-coding RNAs for prediction of the overall survival of glioma patients. *FEBS Open Bio* **2019**, *9* (4), 682-692. DOI: 10.1002/2211-5463.12602 From NLM Medline.
108. Smits, A.; Jin, Z.; Elsir, T.; Pedder, H.; Nister, M.; Alafuzoff, I.; Dimberg, A.; Edqvist, P. H.; Ponten, F.; Aronica, E.; et al. GABA-A channel subunit expression in human glioma correlates with tumor histology and clinical outcome. *PLoS One* **2012**, *7* (5), e37041. DOI: 10.1371/journal.pone.0037041 From NLM Medline.
109. Blanchart, A.; Fernando, R.; Haring, M.; Assaife-Lopes, N.; Romanov, R. A.; Andang, M.; Harkany, T.; Ernfors, P. Endogenous GAB(AA) receptor activity suppresses glioma growth. *Oncogene* **2017**, *36* (6), 777-786. DOI: 10.1038/onc.2016.245 From NLM Medline.
110. Ma, L.; Lin, K.; Chang, G.; Chen, Y.; Yue, C.; Guo, Q.; Zhang, S.; Jia, Z.; Huang, T. T.; Zhou, A.; et al. Aberrant Activation of beta-Catenin Signaling Drives Glioma Tumorigenesis via USP1-Mediated Stabilization of EZH2. *Cancer Res* **2019**, *79* (1), 72-85. DOI: 10.1158/0008-5472.CAN-18-1304 From NLM Medline.
111. Li, Z.; Li, M.; Wang, D.; Hou, P.; Chen, X.; Chu, S.; Chai, D.; Zheng, J.; Bai, J. Post-translational modifications of EZH2 in cancer. *Cell Biosci* **2020**, *10* (1), 143. DOI: 10.1186/s13578-020-00505-0 From NLM PubMed-not-MEDLINE.
112. Nibe, Y.; Oshima, S.; Kobayashi, M.; Maeyashiki, C.; Matsuzawa, Y.; Otsubo, K.; Matsuda, H.; Aonuma, E.; Nemoto, Y.; Nagaishi, T.; et al. Novel polyubiquitin imaging system, PolyUb-FC, reveals that K33-linked polyubiquitin is recruited by SQSTM1/p62. *Autophagy* **2018**, *14* (2), 347-358. DOI: 10.1080/15548627.2017.1407889 From NLM Medline.
113. Chen, Y. H.; Chen, H. H.; Wang, W. J.; Chen, H. Y.; Huang, W. S.; Kao, C. H.; Lee, S. R.; Yeat, N. Y.; Yan, R. L.; Chan, S. J.; et al. TRABID inhibition activates cGAS/STING-mediated anti-tumor immunity through mitosis and autophagy dysregulation. *Nat Commun* **2023**, *14* (1), 3050. DOI: 10.1038/s41467-023-38784-z From NLM Medline.
114. Afonina, I. S.; Beyaert, R. Trabid epigenetically drives expression of IL-12 and IL-23. *Nat Immunol* **2016**, *17* (3), 227-228. DOI: 10.1038/ni.3388 From NLM Medline.

115. Jin, J.; Xie, X.; Xiao, Y.; Hu, H.; Zou, Q.; Cheng, X.; Sun, S. C. Epigenetic regulation of the expression of Il12 and Il23 and autoimmune inflammation by the deubiquitinase TRABID. *Nat Immunol* **2016**, *17* (3), 259-268. DOI: 10.1038/ni.3347 From NLM Medline.
116. Ma, J.; Zhou, Y.; Pan, P.; Yu, H.; Wang, Z.; Li, L. L.; Wang, B.; Yan, Y.; Pan, Y.; Ye, Q.; et al. TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks. *Nat Commun* **2023**, *14* (1), 1810. DOI: 10.1038/s41467-023-37499-5 From NLM Medline.
117. Wertz, I. E.; O'Rourke, K. M.; Zhou, H.; Eby, M.; Aravind, L.; Seshagiri, S.; Wu, P.; Wiesmann, C.; Baker, R.; Boone, D. L.; et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. *Nature* **2004**, *430* (7000), 694-699. DOI: 10.1038/nature02794 From NLM Medline.
118. Wertz, I. E.; Newton, K.; Seshasayee, D.; Kusam, S.; Lam, C.; Zhang, J.; Popovych, N.; Helgason, E.; Schoeffler, A.; Jeet, S.; et al. Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation. *Nature* **2015**, *528* (7582), 370-375. DOI: 10.1038/nature16165 From NLM Medline.
119. Abbasi, A.; Forsberg, K.; Bischof, F. The role of the ubiquitin-editing enzyme A20 in diseases of the central nervous system and other pathological processes. *Front Mol Neurosci* **2015**, *8*, 21. DOI: 10.3389/fnmol.2015.00021 From NLM PubMed-not-MEDLINE.
120. Catrysse, L.; Vereecke, L.; Beyaert, R.; van Loo, G. A20 in inflammation and autoimmunity. *Trends Immunol* **2014**, *35* (1), 22-31. DOI: 10.1016/j.it.2013.10.005 From NLM Medline.
121. Opiari, A. W., Jr.; Boguski, M. S.; Dixit, V. M. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. *J Biol Chem* **1990**, *265* (25), 14705-14708. From NLM Medline.
122. Bredel, M.; Bredel, C.; Juric, D.; Duran, G. E.; Yu, R. X.; Harsh, G. R.; Vogel, H.; Recht, L. D.; Scheck, A. C.; Sikic, B. I. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. *J Clin Oncol* **2006**, *24* (2), 274-287. DOI: 10.1200/JCO.2005.02.9405 From NLM Medline.
123. Hjelmeland, A. B.; Wu, Q.; Wickman, S.; Eyler, C.; Heddleston, J.; Shi, Q.; Lathia, J. D.; Macswords, J.; Lee, J.; McLendon, R. E.; et al. Targeting A20 decreases glioma stem cell survival and tumor growth. *PLoS Biol* **2010**, *8* (2), e1000319. DOI: 10.1371/journal.pbio.1000319 From NLM Medline.
124. Sharma, T.; Schwalbe, E. C.; Williamson, D.; Sill, M.; Hovestadt, V.; Mynarek, M.; Rutkowski, S.; Robinson, G. W.; Gajjar, A.; Cavalli, F.; et al. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. *Acta Neuropathol* **2019**, *138* (2), 309-326. DOI: 10.1007/s00401-019-02020-0 From NLM Medline.
125. Jung, M.; Russell, A. J.; Liu, B.; George, J.; Liu, P. Y.; Liu, T.; DeFazio, A.; Bowtell, D. D.; Oberthuer, A.; London, W. B.; et al. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. *Cancer Res* **2017**, *77* (4), 971-981. DOI: 10.1158/0008-5472.CAN-15-2906 From NLM Medline.
126. Kitamura, H.; Hashimoto, M. USP2-Related Cellular Signaling and Consequent Pathophysiological Outcomes. *Int J Mol Sci* **2021**, *22* (3). DOI: 10.3390/ijms22031209 From NLM Medline.
127. Benassi, B.; Flavin, R.; Marchionni, L.; Zanata, S.; Pan, Y.; Chowdhury, D.; Marani, M.; Strano, S.; Muti, P.; Blandino, G.; et al. MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. *Cancer Discov* **2012**, *2* (3), 236-247. DOI: 10.1158/2159-8290.CD-11-0219 From NLM Medline.
128. Petrosyan, E.; Fares, J.; Fernandez, L. G.; Yeervalli, R.; Dmello, C.; Duffy, J. T.; Zhang, P.; Lee-Chang, C.; Miska, J.; Ahmed, A. U.; et al. Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment. *Mol Cancer Res* **2023**, *21* (5), 389-396. DOI: 10.1158/1541-7786.MCR-22-0920 From NLM Medline.
129. Mitchell, D.; Shireman, J.; Sierra Potchanant, E. A.; Lara-Velazquez, M.; Dey, M. Neuroinflammation in Autoimmune Disease and Primary Brain Tumors: The Quest for Striking the Right Balance. *Front Cell Neurosci* **2021**, *15*, 716947. DOI: 10.3389/fncel.2021.716947 From NLM PubMed-not-MEDLINE.
130. Pelizzari-Raymundo, D.; Doultinos, D.; Pineau, R.; Sauzay, C.; Koutsandreas, T.; Langlais, T.; Carlesso, A.; Gkotsi, E.; Negroni, L.; Avril, T.; et al. A novel IRE1 kinase inhibitor for adjuvant glioblastoma treatment. *iScience* **2023**, *26* (5), 106687. DOI: 10.1016/j.isci.2023.106687 From NLM PubMed-not-MEDLINE.
131. Flores-Santibanez, F.; Rennen, S.; Fernandez, D.; De Nolf, C.; Van De Velde, E.; Gaete Gonzalez, S.; Fuentes, C.; Moreno, C.; Figueroa, D.; Lladser, A.; et al. Nuanced role for dendritic cell intrinsic IRE1 RNase in the regulation of antitumor adaptive immunity. *Front Immunol* **2023**, *14*, 1209588. DOI: 10.3389/fimmu.2023.1209588 From NLM Medline.
132. Liang, W.; Fang, J.; Zhou, S.; Hu, W.; Yang, Z.; Li, Z.; Dai, L.; Tao, Y.; Fu, X.; Wang, X. The role of ubiquitin-specific peptidases in glioma progression. *Biomed Pharmacother* **2022**, *146*, 112585. DOI: 10.1016/j.biopha.2021.112585 From NLM Medline.
133. Hanna, J.; Hathaway, N. A.; Tone, Y.; Crosas, B.; Elsasser, S.; Kirkpatrick, D. S.; Leggett, D. S.; Gygi, S. P.; King, R. W.; Finley, D. Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation. *Cell* **2006**, *127* (1), 99-111. DOI: 10.1016/j.cell.2006.07.038 From NLM Medline.

134. Lee, B. H.; Lee, M. J.; Park, S.; Oh, D. C.; Elsasser, S.; Chen, P. C.; Gartner, C.; Dimova, N.; Hanna, J.; Gygi, S. P.; et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. *Nature* **2010**, *467* (7312), 179-184. DOI: 10.1038/nature09299 From NLM Medline.
135. Lee, J. H.; Shin, S. K.; Jiang, Y.; Choi, W. H.; Hong, C.; Kim, D. E.; Lee, M. J. Facilitated Tau Degradation by USP14 Aptamers via Enhanced Proteasome Activity. *Sci Rep* **2015**, *5*, 10757. DOI: 10.1038/srep10757 From NLM Medline.
136. Zhu, Y.; Zhang, C.; Gu, C.; Li, Q.; Wu, N. Function of Deubiquitinating Enzyme USP14 as Oncogene in Different Types of Cancer. *Cell Physiol Biochem* **2016**, *38* (3), 993-1002. DOI: 10.1159/000443051 From NLM Medline.
137. Ma, Y. S.; Wang, X. F.; Zhang, Y. J.; Luo, P.; Long, H. D.; Li, L.; Yang, H. Q.; Xie, R. T.; Jia, C. Y.; Lu, G. X.; et al. Inhibition of USP14 Deubiquitinating Activity as a Potential Therapy for Tumors with p53 Deficiency. *Mol Ther Oncolytics* **2020**, *16*, 147-157. DOI: 10.1016/j.omto.2019.12.013 From NLM PubMed-not-MEDLINE.
138. Kaokhum, N.; Pinto-Fernandez, A.; Wilkinson, M.; Kessler, B. M.; Ismail, H. M. The Mechano-Ubiquitinome of Articular Cartilage: Differential Ubiquitination and Activation of a Group of ER-Associated DUBs and ER Stress Regulators. *Mol Cell Proteomics* **2022**, *21* (12), 100419. DOI: 10.1016/j.mcpro.2022.100419 From NLM Medline.
139. Ernst, R.; Mueller, B.; Ploegh, H. L.; Schlieker, C. The otubain YOD1 is a deubiquitinating enzyme that associates with p97 to facilitate protein dislocation from the ER. *Mol Cell* **2009**, *36* (1), 28-38. DOI: 10.1016/j.molcel.2009.09.016 From NLM Medline.
140. Schimmack, G.; Schorpp, K.; Kutzner, K.; Gehring, T.; Brenke, J. K.; Hadian, K.; Krappmann, D. YOD1/TRAF6 association balances p62-dependent IL-1 signaling to NF-kappaB. *Elife* **2017**, *6*. DOI: 10.7554/eLife.22416 From NLM Medline.
141. Tanji, K.; Mori, F.; Miki, Y.; Utsumi, J.; Sasaki, H.; Kakita, A.; Takahashi, H.; Wakabayashi, K. YOD1 attenuates neurogenic proteotoxicity through its deubiquitinating activity. *Neurobiol Dis* **2018**, *112*, 14-23. DOI: 10.1016/j.nbd.2018.01.006 From NLM Medline.
142. Zhou, L.; Li, L.; Chen, Y.; Chen, C.; Zhi, Z.; Yan, L.; Wang, Y.; Liu, B.; Zhai, Q. miR-190a-3p Promotes Proliferation and Migration in Glioma Cells via YOD1. *Comput Math Methods Med* **2021**, *2021*, 3957738. DOI: 10.1155/2021/3957738 From NLM Medline.
143. Kim, Y.; Kim, W.; Song, Y.; Kim, J. R.; Cho, K.; Moon, H.; Ro, S. W.; Seo, E.; Ryu, Y. M.; Myung, S. J.; et al. Deubiquitinase YOD1 potentiates YAP/TAZ activities through enhancing ITCH stability. *Proc Natl Acad Sci U S A* **2017**, *114* (18), 4691-4696. DOI: 10.1073/pnas.1620306114 From NLM Medline.
144. Masliantsev, K.; Karayan-Tapon, L.; Guichet, P. O. Hippo Signaling Pathway in Gliomas. *Cells* **2021**, *10* (1). DOI: 10.3390/cells10010184 From NLM Medline.
145. Nijman, S. M.; Huang, T. T.; Dirac, A. M.; Brummelkamp, T. R.; Kerkhoven, R. M.; D'Andrea, A. D.; Bernards, R. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. *Mol Cell* **2005**, *17* (3), 331-339. DOI: 10.1016/j.molcel.2005.01.008 From NLM Medline.
146. Huang, T. T.; Nijman, S. M.; Mirchandani, K. D.; Galardy, P. J.; Cohn, M. A.; Haas, W.; Gygi, S. P.; Ploegh, H. L.; Bernards, R.; D'Andrea, A. D. Regulation of monoubiquitinated PCNA by DUB autocleavage. *Nat Cell Biol* **2006**, *8* (4), 339-347. DOI: 10.1038/ncb1378 From NLM Medline.
147. Kashiwaba, S.; Kanao, R.; Masuda, Y.; Kusumoto-Matsuo, R.; Hanaoka, F.; Masutani, C. USP7 Is a Suppressor of PCNA Ubiquitination and Oxidative-Stress-Induced Mutagenesis in Human Cells. *Cell Rep* **2015**, *13* (10), 2072-2080. DOI: 10.1016/j.celrep.2015.11.014 From NLM Medline.
148. Parsons, J. L.; Dianova, II; Khoronenkova, S. V.; Edelman, M. J.; Kessler, B. M.; Dianov, G. L. USP47 is a deubiquitylating enzyme that regulates base excision repair by controlling steady-state levels of DNA polymerase beta. *Mol Cell* **2011**, *41* (5), 609-615. DOI: 10.1016/j.molcel.2011.02.016 From NLM Medline.
149. Zhao, Y.; Majid, M. C.; Soll, J. M.; Brickner, J. R.; Dango, S.; Mosammamaparast, N. Noncanonical regulation of alkylation damage resistance by the OTUD4 deubiquitinase. *EMBO J* **2015**, *34* (12), 1687-1703. DOI: 10.15252/embj.201490497 From NLM Medline.
150. Chitale, S.; Richly, H. Timing of DNA lesion recognition: Ubiquitin signaling in the NER pathway. *Cell Cycle* **2017**, *16* (2), 163-171. DOI: 10.1080/15384101.2016.1261227 From NLM Medline.
151. Perez-Oliva, A. B.; Lachaud, C.; Szytiarski, P.; Munoz, I.; Macartney, T.; Hickson, I.; Rouse, J.; Alessi, D. R. USP45 deubiquitylase controls ERCC1-XPF endonuclease-mediated DNA damage responses. *EMBO J* **2015**, *34* (3), 326-343. DOI: 10.15252/embj.201489184 From NLM Medline.
152. Nishi, R.; Wijnhoven, P.; le Sage, C.; Tjeertes, J.; Galanty, Y.; Forment, J. V.; Clague, M. J.; Urbe, S.; Jackson, S. P. Systematic characterization of deubiquitylating enzymes for roles in maintaining genome integrity. *Nat Cell Biol* **2014**, *16* (10), 1016-1026, 1011-1018. DOI: 10.1038/ncb3028 From NLM Medline.

153. Sato, Y.; Yamagata, A.; Goto-Ito, S.; Kubota, K.; Miyamoto, R.; Nakada, S.; Fukai, S. Molecular basis of Lys-63-linked polyubiquitination inhibition by the interaction between human deubiquitinating enzyme OTUB1 and ubiquitin-conjugating enzyme UBC13. *J Biol Chem* **2012**, *287* (31), 25860-25868. DOI: 10.1074/jbc.M112.364752 From NLM Medline.
154. Butler, L. R.; Densham, R. M.; Jia, J.; Garvin, A. J.; Stone, H. R.; Shah, V.; Weekes, D.; Festy, F.; Beesley, J.; Morris, J. R. The proteasomal de-ubiquitinating enzyme POH1 promotes the double-strand DNA break response. *EMBO J* **2012**, *31* (19), 3918-3934. DOI: 10.1038/emboj.2012.232 From NLM Medline.
155. Kakarougkas, A.; Ismail, A.; Katsuki, Y.; Freire, R.; Shibata, A.; Jeggo, P. A. Co-operation of BRCA1 and POH1 relieves the barriers posed by 53BP1 and RAP80 to resection. *Nucleic Acids Res* **2013**, *41* (22), 10298-10311. DOI: 10.1093/nar/gkt802 From NLM Medline.
156. Vincent, P.; Collette, Y.; Marignier, R.; Vauillat, C.; Rogemond, V.; Davoust, N.; Malcus, C.; Cavagna, S.; Gessain, A.; Machuca-Gayet, I.; et al. A role for the neuronal protein collapsin response mediator protein 2 in T lymphocyte polarization and migration. *J Immunol* **2005**, *175* (11), 7650-7660. DOI: 10.4049/jimmunol.175.11.7650 From NLM Medline.
157. Nakamura, F.; Ohshima, T.; Goshima, Y. Collapsin Response Mediator Proteins: Their Biological Functions and Pathophysiology in Neuronal Development and Regeneration. *Front Cell Neurosci* **2020**, *14*, 188. DOI: 10.3389/fncel.2020.00188 From NLM PubMed-not-MEDLINE.
158. Bedekovics, T.; Hussain, S.; Zhang, Y.; Ali, A.; Jeon, Y. J.; Galardy, P. J. USP24 Is a Cancer-Associated Ubiquitin Hydrolase, Novel Tumor Suppressor, and Chromosome Instability Gene Deleted in Neuroblastoma. *Cancer Res* **2021**, *81* (5), 1321-1331. DOI: 10.1158/0008-5472.CAN-20-1777 From NLM Medline.
159. Thayer, J. A.; Awad, O.; Hegdekar, N.; Sarkar, C.; Tesfay, H.; Burt, C.; Zeng, X.; Feldman, R. A.; Lipinski, M. M. The PARK10 gene USP24 is a negative regulator of autophagy and ULK1 protein stability. *Autophagy* **2020**, *16* (1), 140-153. DOI: 10.1080/15548627.2019.1598754 From NLM Medline.
160. Ma, X.; Qi, W.; Yang, F.; Pan, H. Deubiquitinase JOSD1 promotes tumor progression via stabilizing Snail in lung adenocarcinoma. *Am J Cancer Res* **2022**, *12* (5), 2323-2336. From NLM PubMed-not-MEDLINE.
161. Yang, J.; Weisberg, E. L.; Liu, X.; Magin, R. S.; Chan, W. C.; Hu, B.; Schauer, N. J.; Zhang, S.; Lamberto, I.; Doherty, L.; et al. Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. *Leukemia* **2022**, *36* (1), 210-220. DOI: 10.1038/s41375-021-01336-9 From NLM Medline.
162. Wang, X.; Zhang, L.; Zhang, Y.; Zhao, P.; Qian, L.; Yuan, Y.; Liu, J.; Cheng, Q.; Xu, W.; Zuo, Y.; et al. JOSD1 Negatively Regulates Type-I Interferon Antiviral Activity by Deubiquitinating and Stabilizing SOCS1. *Viral Immunol* **2017**, *30* (5), 342-349. DOI: 10.1089/vim.2017.0015 From NLM Medline.
163. Luo, Y.; Zhou, J.; Tang, J.; Zhou, F.; He, Z.; Liu, T.; Liu, T. MINDY1 promotes bladder cancer progression by stabilizing YAP. *Cancer Cell Int* **2021**, *21* (1), 395. DOI: 10.1186/s12935-021-02095-4 From NLM PubMed-not-MEDLINE.
164. Tang, J.; Luo, Y.; Long, G.; Zhou, L. MINDY1 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha. *Cell Death Dis* **2021**, *12* (10), 937. DOI: 10.1038/s41419-021-04244-z From NLM Medline.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.